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1. Tuberculosis as a global disease 
Tuberculosis (TB), one of the oldest recorded scourges of mankind, is still one of 
the biggest killers among the communicable diseases from a single infectious 
agent. In facts, despite the availability of effective short course chemotherapies 
(Directly Observed Treatment Short course-DOTS), the Bacille Calmettee-Guerin 
(BCG) vaccine and the use of modern antibiotics, TB ranks alongside the human 
immunodeficiency virus (HIV) as a leading cause of mortality worldwide. TB is a 
major global health problem that causes ill-health among millions of people each 
year, with a devastating social and financial impact. 
 
Figure 1: Estimated new TB incident rates (TB cases per year per 100 000 population per 
year) in 2014 [1] 
According to the latest Global Tuberculosis Report from World Health 
Organization (WHO) [1], in 2014 there were an estimated 9.6 million new TB 
  Chapter 1 
2 
 
cases, among which 5.4 million were men, 3.2 million were women and 1.0 million 
were children (Figure 1). Amidst of these new TB cases, 58% were found in South-
East Asia and Western Pacific regions, and 20% in Africa. Notably countries like 
India, China, and Indonesia had the highest number of emerging TB cases that are 
23%, 10% and 10% of the global total, respectively. There were also 1.5 million 
TB deaths which includes 1.1 million HIV-negative people and 0.4 million HIV-
positive people. 
The co-epidemics of TB and HIV is a TB issue that needs to be addressed, at the 
light of the observation that an estimated 12% of the 9.6 million of new TB cases 
were found HIV-positive [1]. 
TB is widely recognized in low-income countries, showing the greatest incidence 
rates in the poorer section of the community, where risk factors such as the lack of 
basic health services, poor nutrition, alcoholism and inadequate living conditions 
contribute to the spreading of the disease. Although TB strongly correlates with 
poverty, a main TB concern is the long-term multi-drug treatment regimen, leading 
to anticipated non-compliance of the patient and/or resulting in increased drug 
toxicity, with escalating mortality rates due to detrimental side-effects. This 
situation is further aggravated by the observation that, often as a consequence of 
premature termination of drug therapy, a steadily increasing number of drug 
resistant TB cases is reported, whose treatment is more challenging, thus allowing 
TB to reach pandemic proportions [2]. 
2. Mycobacterium tuberculosis 
Mycobacterium tuberculosis (MTB), the highly predominant causative agent of TB 
in humans, is a member of the so called “Mycobacterium tuberculosis complex” 
(MTBC), a group of genetically related mycobacterial species. MTBC also includes 
M. bovis (the etiological agent of TB in cattle), and its live-attenuated BCG strain, 
which is at present the only approved vaccine used in human TB prophylaxis [3]. 
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Similar to the vast majority of mycobacteria, MTB is a non-motile, non-
sporulating, acid-fast Gram-positive bacillus that appears microscopically as a 
straight or slightly curved rod, 1 to 4 µm in length and 0.3 to 0.6 µm wide. Other 
worth mentioning characteristics of MTB are its slow generation time (approx. 24 
hours in synthetic medium or in animal models), which is mainly due to the 
presence of a tough, complex cell wall; the capability to enter in a dormant state 
that can last for long periods; the peculiar strategies adopted for intracellular 
survival and reactivation; the high GC-content of its genomic DNA and an overall 
high level of genetic stability [4]. 
In order to isolate and cultivate MTB in vitro, Middlebrook´s and Lowenstein-
Jensen (L-J) media are most commonly used, at a growth optimum temperature of 
37°C; in the case of growth on solid media, 4-5 weeks are needed for small and 
slightly buff colored MTB colonies becoming visible to the naked eye (Figure 2A). 
As other acid-fast bacteria, MTB could be easily visualized by Ziehl-Neelsen (or 
acid-fast) staining, whose pattern is characterized by a poor absorption quality and 
a high stain retention capacity, making the MTB bacilli bright red and emerging 
out clearly against the backdrop (Figure 2B) [5]. 
 
Figure 2: (A) Colonies of MTB on L-J medium against the blue backdrop. (B) Acid-fast MTB 
emerging out as bright red cells [5]  
Many of the peculiar MTB features depend on its cell wall, which is different 
from both Gram-positive and Gram-negative bacteria. As shown in the Figure 3 
(panel B), and moving from the inner plasma membrane towards the surface of the 
A B 
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bacillus, three covalently linked layers can be identified in the MTB cell wall 
skeleton, built up by peptidoglycan, arabinogalactan and mycolic acids. In 
particular, the outer part of the mycolic acid layer (also called mycomembrane) 
contains various free lipids -like lipoarabinomannan (LAM), lipomannan, phenolic 
gycolipids, phthiocerol dimycocerosates, threalose dimycolate (cord factor), 
sulpholipids and phosphatidylinositol mannosides that are interposed with mycolic 
acids. The outermost layer of the MTB cell wall is represented by the capsule, 
which is mainly composed of polysaccharides [6]. 
 
Figure 3: (A) Scanning electron microscope image of M. tuberculosis; (B) Schematic 
representation of mycobacterial cell wall [adapted from 5 and 8] 
Among all the components of the mycobacterial waxy cell wall, three major 
fractions that deserves attention are the mycolic acids, cord factor (threalose-6,6-
dimycolate) (Figure 4), and the wax-D, which together confer many of the unique 
characteristics of this genus such as acid-fastness, hindrance to crystal violet 
(differently from genuine Gram-positive bacteria), extreme hydrophobicity, 
resistance to drying, acidity/alkalinity, and many antibiotics, as well as distinctive 
immuno-stimulatory properties [5], therefore playing a crucial role in TB 
pathogenesis. 




Figure 4: The cord factor is responsible for the unique feature of MTB known as serpentine 
cording, resulting in the formation of rope-like tangles (A) phenotype typically associated with 
virulent strain [9] (A) Acid-fast stained MTB cells showing serpentine cording (B) Chemical 
structure of cord factor (Tetrahalose 6,6´-dimycolate)[adapted from10,11]. 
 3. Pathogenesis of TB in human 
The pathogenesis process of TB in humans can be divided in several stages that are 
depicted below: 
Transmission through aerosol droplets 
MTB bacilli are carried in air-borne particles termed droplet nuclei of 1-5 µm in 
diameter and that are exhaled, in the form of aerosol, by individuals who have 
laryngeal or pulmonary active TB disease, by coughing, sneezing or talking (Figure 
5A). Depending on the environmental conditions, these infected aerosol droplets 
can remain suspended in the air for several hours before inhalation by a healthy 
subject. Two important factors that affect the rate of survival of mycobacteria at 
this stage are desiccation and UV irradiation [12,13]. The success of the infection 
of exposed individuals also depends upon the frequency and the duration of the 
exposure, and the concentration and the size of the droplet nuclei. Indeed, once 
inhaled, the MTB-infected particles make their way through the upper respiratory 
tract (i.e. throat or nasal passages, where the infection is unlikely to develop); the 
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smaller nuclei then traverse towards the bronchi to reach the alveoli of the lungs 
where the primary infection can begin [14]. 
 
Figure 5: (A) Transmission through aerosol droplet [15] (B) Three alternative fates of MTB 
following infection: 1) elimination by host immune system, 2) containment (as  latent TB 
infection), 3) progression towards full-blown active disease [ modified from 16]. 
Alveolar Macrophage infection 
Inside the lung alveoli MTB bacilli are ingested by resident phagocytes (i.e., the 
alveolar macrophages and dendritic cells), or, alternatively, by monocytes recruited 
from peripheral blood. MTB appears to gain entry into the macrophages via cell-
surface molecules like complement receptor, mannose receptor, Fc and scavenger 
receptors [17]. Mainly due to the immune system status of the host, the initial 
infection can be either wiped out (resulting in an abortive infection), or contained 
as a latent TB (in the vast majority of the cases), or it can progress towards the full 
blown active disease, including the uncontrolled MTB bacilli proliferation and 
spread to other organs (Figure 5B) [18]. 
Macrophages are the primary defense against microbial invaders, due to their 
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efficiency in internalizing microbes, engulfing them into phagosomes, and 
promoting the phagosome-lysosome fusion, that finally leads to the destruction of 
the cargo (Figure 6). Phagosome-confined pathogens experience stressful 
conditions like i) an increased acidification, ii) the exposure to highly reactive 
oxygen species (ROS) and reactive nitrogen intermediates (RNI) -generated by the 
host cell enzymes NADPH phagocyte oxidase and inducible nitric oxide synthase 
(iNOS)-, that can damage the captured microbes by modifying their DNA, lipids, 
proteins and active centers of metal-dependent proteins (like iron-containing 
siderophore), and iii) the release of hydrolytic enzymes and cationic antimicrobial 
peptides [19,20]. 
 
Figure 6: Schematic representation of macrophage showing the main steps of the process 
leading to microbial invaders elimination [21] 
As a well-adapted intracellular pathogen, MTB evolved unique survival strategies 
to persist successfully within macrophages. In particular, inside the phagosome, 
MTB can fight the aforesaid hazardous acts at multiple levels. First, the bacilli 
interfere with the host intracellular trafficking pathways by modulating events in 
endosomal/phagosomal maturation pathway, and hampering the phagosome-
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lysosome fusion; the delivery to lysosomes is also prevented by the retention of the 
host TACO protein (tryptophan aspartate-containing coat protein) on the 
cytoplasmic surface of the MTB-harboring phagosome membrane. Moreover, 
MTB limits an excessive acidification by blocking the proton-ATPase pumps 
(normally reducing neutral pH to acidic pH), with the concomitant secretion of 
mycobacterial urease, an enzyme producing neutralizing ammonia from urea; 
finally MTB produces enzymes (like catalase-peroxidase and superoxide 
dismutase) for neutralizing the effects of oxidative radicals (Figure 7) [21,22]. 
Overall, these phenomena allow MTB to stably settle within the macrophages, 
which are among the most inhospitable cells of the body. 
 
Figure 7: Some of the survival strategies used by MTB inside activated macrophages to evade 
host cell defense [adapted from 21] 
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Formation of Granuloma 
To contain the dissemination of the infection, infected macrophages, laden with 
replicating MTB, induce a pro-inflammatory response that recruits other cells, in a 
well-defined order; this process leads to the formation of the granuloma (or 
tubercle), the hallmark of TB, that provides a niche where the MTB bacilli could 
reside for long periods of time, evading the host immune response, and establishing 
the asymptomatic, non-contagious, latent phase of the disease (Latent Tuberculosis 
Infection, LTBI) [23]. This structure is maintained and stabilized by events 
mediated by a delicate cross-talk between the host and the pathogen. Moreover, the 
unfavorable conditions inside the granuloma, such as nutrient limitation and low 
oxygen tension, restricts the metabolic activities of subpopulations of MTB bacilli 
leading to their dormancy [18]. 
In humans, the TB granulomas show a high histological/morphological plasticity 
and three major types can be distinguished, which are not independent entities but 
forms a continuum. These formations are i) the solid granuloma, typifying the 
containment phase of the infection; ii) the necrotic granuloma, characterizing the 
early stages of active TB; and iii) the caseous granuloma, typically observed at the 
end-stage of the disease or in severe TB (Figure 8). 
The solid granulomas that prevail during LTBI, is composed of mononuclear 
phagacytes, dendritic cells along with T and B lymphocytes. The central part is 
predominated by mononuclear phagocytes, fibroblasts and dendritic cells while the 
lymphocytes form the outer ring. Solid granuloma is typically surrounded by a 
fibrotic wall, and has a low burden of MTB with low metabolic activity (dormant 
bacilli). The necrotic granuloma remains well-structured but forms necrotic center 
consisting of solid cell debris. This architecture has lower access to blood vessel 
inducing hypoxia and starvation conditions. In the caseous granuloma, the center 
liquefies, leading to cavity formation followed by reestablishing normal oxygen 
tension. Moreover, caseous material represent an abundant source of nutrients 
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enhancing the resuscitation and the multiplication of the pathogen. This stage 
finally allows MTB bacilli to gain access to the alveolar space paving their way to 
dissemination [18,24]. 
 
Figure 8: The complete TB cycle, mainly focused on granuloma maturation stages [18] 
Reactivation of infection 
The containment of the infection within granuloma declines when the immune 
status of the host changes, as a consequence of old age, malnutrition, drug-induced 
immune-suppression, or during co-infection with HIV. This results in progression 
from LTBI to active TB. At this stage, caseating granuloma degenerate, followed 
by the rupture and spilling of thousands of viable infectious bacilli into the lung 
airways. The development of productive coughing promotes the release of MTB-
infected aerosols into the environment and the potential spread of infectious bacilli 
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to other people (Figure 8) [23]. The progression from LTBI to TB disease may 
occur at any time, from soon to many years later after infection. 
Taken as a whole, the complexity of the MTB life cycle, and the multifarious 
ways the bacillus evolved to escape the host’s immune defenses, explain the MTB 
considerable success as a human pathogen, while posing a great challenge to TB 
eradication. 
4. TB diagnosis and therapy 
The containment of TB spread is based on improved diagnostic methods and early 
antibiotic therapy, as the potency of BCG-vaccination against TB caters limited 
protection during childhood and also significantly varies among population [25 and 
references therein]. 
TB diagnosis 
Last decade has seen significant advances in the methodology of TB diagnosis 
since the acid fast bacilli smear microscopy was insufficient to deal with the dual 
issue of drug-resistance TB and HIV-associated TB. There are several TB detection 
methods, like phenotypic methods (e.g. thin-layer agar, colour test, the microscopic 
observation drug susceptibility assay); genotypic methods (e.g. Real-time PCR, and 
sequencing); immunological methods (detection of antibodies/antigen); and also 
typical techniques like Interferon-Gamma Release Assays. Particular 
methodologies including automated real-time polymerase chain reaction (PCR)-
based test truly revolutionizes the diagnosis of drug-resistant TB. However, little 
progress has been made in search of a true point-of-care test for TB. Thus, an 
impetus is needed for the development of rapid as well as accurate TB diagnostics 
for the lowest level of the health system, where the tuberculin test, radiographic 
analysis (chest X-ray) and sputum culture still represent the only means of 
diagnosis that are often not accurate [26,27]. 
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Anti-TB drugs and treatment Regimen 
As reported by WHO, multi-drug therapy is comprised of an initial intensive phase 
during which 3-4 first-line drugs i.e. rifampicin (RIF), isoniazid (INH), 
pyrazinamide (PYZ), ethambutol (ETB) and streptomycin- are administered daily 
for 2 months, followed by the continuation phase, consisting in the administration 
of RIF and INH for next 4 months, either daily or 3 times per week [28]. 
 
Figure 9: Sites of action of principal anti-TB drugs [29] 
INH together with streptomycin and ETB kills most of the rapidly replicating 
bacilli in the first 2 weeks of treatment. On the other hand, RIF eradicates slow or 
non-replicating organisms while the high sterilizing effect of PYZ serves to act on 
  Chapter 1 
13 
 
semi-dormant bacilli that remain unaffected by other anti-TB agents. The most 
potent anti -TB drug combination, INH and RIF, kill more than 99% of tubercular 
bacilli within 2 months of the initiation phase of the therapy. The sites of action of 
these principal anti-TB agents are shown in (Figure 9) [28,29]. 
The long-term multi-drug treatment regimen required for curing active TB, 
together with the absence of drugs targeting the latent disease, and therefore 
reducing the proportions of the MTB reservoir, contribute to make the global TB 
management and treatment far from being satisfactory, especially considering the 
warring phenomenon of MTB drug resistance. 
5. MTB Drug-Resistance  
Inadequate drugs with improper drug dosages, irregular treatment or even 
administration of a single drug to a failing regimen allows the selective growth of 
drug-resistant pathogens and/or acquisition of a drug resistant phenotype by a 
previously sensitive organism, thus imposing the drug resistance phenomenon as a 
“man-made” event.  
Epidemiologically, drug resistance phenomenon in TB is classified into two 
types.  
- Primary drug resistance: this situation is observed in untreated patients that are 
found to have drug-resistant bacilli, and is most frequently due to a new infection 
by a drug resistant strain. 
 - Secondary drug resistance: this situation develops during TB therapy because of 
inadequate, improper and irregular prescribed treatment regimen or incomplete 
capacitance to medication protocols; it could  also be due to other conditions like 
drug mal-absorption or drug-drug interaction causing low serum levels [30]. 
As a consequence of improper administration of prescribed TB drug regimen, or 
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due to abrupt augmentation of medicines by TB affected individuals, different 
drug-resistant strains of MTB develop leading to multi-drug resistant TB (MDR-
TB), extensively-drug resistant TB (XDR-TB) and total drug resistant TB (TDR-
TB). 
- MDR-TB: is defined by the resistance to the two most commonly used drugs in 
first-line TB therapy, INH and RIF. The main causes of MDR-TB are poor patient 
management, non-adherence to the prescribed regimen, a poor national program or 
sometimes a combination of all these three [31]. According to the latest WHO 
report, in 2014 an estimated 190,000 people died of MDR-TB [1]. 
 - XDR-TB: is defined by the resistance to any fluoroquinolone, and at least one of 
three injectable second-line drugs (capreomycin, kanamycin, and amikacin), in 
addition to INH and RIF, making XDR-TB medication extremely complicated, and 
representing an increasing health problem [32]. 
- TDR-TB: most recently MTB strains which are resistant to all kinds of first- and 
second-line drugs developed thus, is posing a major global health concern [33]. 
In many bacteria, the genetic determinants of the drug-resistance phenomenon are 
carried through mobile elements that, by promoting the horizontal transfer of 
genetic material, drive the evolution and adaptation of the microbe. On contrast, in 
MTB, horizontal transfer of resistance genes via plasmids or transposons has not 
been reported, and all currently well-studied acquired resistances are mediated 
through chromosomal mutations that arise spontaneously or under the selective 
pressure of antibiotics use. This kind of drug resistance is called “acquired 
resistance” and the MTB genes involved are shown in Table 1 [34,35]. 
Another type of drug resistance that is seen in MTB is the intrinsic antibiotic 
resistance. This kind of resistance can be offered either by the presence of the 
complex mycobacterial cell wall per se (e.g. the penetration of β-lactams through 
the MTB cell wall is hundreds fold slower than in E. coli), or by specialized 
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mechanisms that allow the active neutralization/elusion of antibiotic actions [35]. 
Extensive MTB genomic analyses together with comparative studies reveal that 
the genes repertoire coding for proteins involved in DNA Replication, 
Recombination and Repair (the so called “3R-genes”), shows a level of sequence 
variability that is significantly higher than that characterizing the house-keeping 
genes, a feature that could promote the incidence and/or allow the fixation of 
spontaneous mutations elsewhere in the genome, finally contributing also to the 
emergence of drug resistance [36]. 
Table 1: Genes involved in acquired antibiotic resistance in MTB [35]. 
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6. MTB Genome stress and DNA Repair  
At all stages of its life MTB is confronted by a variety of environmental and 
endogenous physical and chemical stresses that could produce genotoxic damage, 
posing a great threat to the integrity of the mycobacterial genome (Figure 10) [37]. 
 
Figure 10: MTB life cycle and associated stress [37] 
On the opposite end, the occurrence of spontaneous mutations which could 
augment the fitness of the bacilli under specific selective pressures (e.g. mutations 
conferring drug resistance to anti-tubercular drug), is a prerequisite for adaptability 
to changing environment/conditions during the complex infection cycle. Therefore, 
while efficient DNA repair mechanisms must operate in MTB to avoid the 
deleterious and/or irreversible effects of DNA damage on chromosome stability, a 
certain degree of damage tolerance must be there to accommodate the evolutionary 
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imperative to adaptation [38]. 
Extensive MTB genomic analyses, together with a more limited number of gene 
inactivation studies, have identified components of most of the DNA repair 
pathways which are active in other species, including multi-enzymatic systems like 
Nucleotide excision repair (NER), Base Excision Repair (BER) and recombination 
repair systems -with the notable exception of canonical Mismatch Repair (MMR) 
components (Figure 11), as well as proteins responsible for Direct Reversal of 
DNA-damage [37,39,40]. Together these systems allow the MTB bacilli to deal 
with the great majority of genotoxic and/or mutagenic insults they encounter during 
their life (Figure 10), that can produce DNA damage in the form of single 
nucleotide polymorphisms (SNPs, both synonymous and non-synonymous), 
frameshifts, insertion/deletion, oxidation, deamination, alkylation, and DNA strand 
breaks. 
 
Figure 11: All multi-step repair pathway in MTB [adapted from 42]. The nucleotide Excision 
Repair pathway will be described in details in the following section. 
 
  Chapter 1 
18 
 
In the form of contaminated aerosol droplets, at the first stage of infection, MTB 
is exposed to major genotoxic factors, namely UV irradiation and desiccation, 
affecting bacilli rate of survival. UV irradiation damages the DNA causing 
cyclobutane pyrimidine dimers which can be removed by NER; the desiccation of 
bacilli-infected droplets leads to double-stranded breaks (DSBs) that can be 
repaired mainly by homologous recombination (HR) and non-homologous end 
joining (NHEJ) [41]. During the following stage of TB pathogenesis, that is during 
the MTB persistence inside the infected macrophages inside the granuloma, the 
bacilli are mainly exposed to host-generated antimicrobial ROS and RNI, 
starvation and hypoxia, which induce DNA damages that can be counteracted by 
the concerted actions of all the DNA-repair systems (reviewed in [37,42] and 
reference therein). 
However, our current knowledge of the reciprocal co-ordination of the 
mechanisms ensuring MTB genome integrity, and of the integration of the DNA 
repair toolkit encoded functions into an ensemble view of the DNA metabolism 
during the entire MTB life, is still somehow fragmentary. 
7. The Nucleotide Excision Repair (NER) system 
Much of the current comprehension of NER comes from the seminal work carried 
out in Escherichia coli [43], by Prof. Aziz Sancar who was honored by the Nobel 
Prize in Chemistry, 2015. 
NER is a major DNA repair mechanism which is highly conserved among all 
biological systems, although performed by different proteins in prokaryotes and 
higher eukaryotes. NER importance is reflected by its broad substrate specificity, 
which includes UV-induced photoproducts, alkylated bases, DNA crosslinks, and 
bulky anti-cancer drug-DNA adducts. 
In humans, three severe diseases are associated with defects in NER: xeroderma 
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pigmentosum, Cockayne´s syndrome and trichothiodystrophy [44]. 
In Eubacteria and some Archaea, the first steps in NER (namely the damage 
tracking and recognition, followed by a dual incision at both side of the lesion), are 
carried out by the coordinated action of the UvrA, UvrB and UvrC proteins (often 
referred to as the “UvrABC” endonuclease). Based upon biochemical and structural 
data, the most recent models of the tracking complex from Geobacillus 
stearothermophilus, involve the assembling of an UvrA2:UvrB2 heterotetramer, 
which possesses the ability to locate sites of potential damage by virtue of the local 
DNA distortion, in an ATP-dependent UvrA-mediated process [45]. Once the 
lesion is recognized, the molecular architecture of the UvrA/UvrB/DNA complex 
undergoes a substantial rearrangement that frees the UvrA component from the 
ensemble, leaving UvrB stably associated to the modified DNA strand (pre-incision 
complex). The endonuclease UvrC is then recruited to the site of damage, where it 
performs two single-strand incisions, four and eight phosphodiester bonds away 
from the 3’- and 5'-side of the lesion, respectively. The dual incision creates a 12- 
residue long oligonucleotide containing the lesion. The DNA helicase II (UvrD) is 
then required to release UvrC and the excised oligonucleotide, while the DNA 
polymerase I fills the gap (using the complementary intact strand as the template), 
displacing the UvrB component during the synthesis. Finally the DNA ligase I, 
encoded by the LigA gene, seals the nick thus restoring the integrity of the double 
helix. This branch of NER is called Global Genome Repair (GGR) (Figure 12) 
[46]. 
Interestingly, the stalling of RNA polymerase (RNAP) at damaged DNA sites 
triggers an important branch of NER, the Transcription Coupled Repair (TCR) 
(Figure 12), whose activity is required to repair in real time actively transcribed 
genes. In most bacteria including MTB, TCR is mediated by the Mfd protein [47], 
a homolog of the eukaryotic transcription-repair coupling factor (TRCF). By 
binding the N-terminus of the RNA polymerase -subunit [48], Mfd initiates a 
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cascade of events which ensure the removal of the stalled RNA polymerase from 
the site of damage and the recruitment of the NER components to perform the 











Figure 12: Steps of NER in eubacteria (TCR and GGR-NER) [49] 
All NER components are conserved in MTB, highlighting the importance of this 
system in the maintenance of mycobacterial genome integrity. In particular 
concerning the UvrABC endonuclease, mycobacteria are found to up-regulate the 
expression level of the key players of NER like UvrA and UvrB, on exposure to 
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hydrogen peroxide [49,51]. Moreover, a mutant MTB strain, in which the uvrA 
gene was inactivated, was found sensitive to various methylating agents. Finally a 
recombinant version of UvrA possesses the expected DNA-dependant ATPase 
activity and substrate specificities [52].  Similarly, UvrB was found to be important 
for bacterial survival using transposon mutagenesis screen. MTB deficient of UvrB 
also displayed sensitivity to acidified sodium nitrite, a major source of RNI. 
Further analysis disclosed that UvrB mutants displayed reduced survival rate 
within mouse model of infection [53]. UvrC gene expression level is enhanced 
within infected activated macrophages [54]. All the aforesaid observations, signal 
NER components as a useful drug target. 
8. Direct Reversal of alkylated-DNA 
Alkylating agents constitutes a wide class of highly reactive compounds of 
endogenous and exogenous origin that can damage the majority of cellular 
structures and macromolecules, including the DNA, and therefore being endowed 
with an extremely dangerous cytotoxic and mutagenic potential (Figure 13). 
 
Figure 13: The type of DNA damage expected to be sustained in MTB and the genes 
implicated in damage repair and reversal [38] 
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In bacterial species, including MTB, DNA alkylation can be counteracted either 
by exploiting multi-enzymatic systems (e.g. NER and BER) or by mounting an 
adaptive response, the Ada response [55,40]. 
In E. coli the Ada operon consists of four genes: ada (depicted as adaA-adaB in 
Figure 14 A), alkA, alkB and aidB. The Ada protein is a methyltransferase that also 
acts as the positive regulator of the operon; the AlkA protein is a 3-methyl-adenine 
(3mA) DNA glycosylase; the AlkB protein is a Fe(II)-dependent dioxygenase that 
repairs lesions such as 1-methyladenine (1-mA) and 3methylcytosine (1-mC), by 
catalyzing oxidative demethylation; finally AidB is a DNA-binding protein 
predicted to catalyze direct repair of alkylated DNA[56].  
More in details, E. coli Ada is composed by two domains, the N-terminal AdaA 
and the C-terminal AdaB domain. The 20 kDa AdaA domain transfers the methyl 
group of innocuous methylphosphotriesters in DNA onto the cysteine residue of its 
active site; this methylation converts the protein into a transcriptional activator with 
specific DNA binding affinity to genes having the ada operator sequence in their 









-meT) bases by transferring 
the alkyl group to a strictly conserved cysteine of its active site, in an irreversible 
suicidal reaction [56,57]. 
 
Figure 14: Comparison of Ada operon in E.coli and MTB [adapted from 40] 
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Although adaptive response is conserved among many bacterial species, the 
domains of Ada (namely AdaA and AdaB), AlkA and AlkB proteins exist in 
different combinations in different prokaryotes. In particular, MTB shows a gene 
fusion of adaA with alkA (adaA-alkA), and an independent adaB gene (Tuberculist 
code: Rv1316c; annotated in several databases as ogt, to put the accent onto the 
biochemical function of the corresponding protein, the O
6
-methylguanine 
methyltransferase (OGT) (Figure 14 B). 
Transcription of the adaA-alkA and adaB genes are induced in MTB when treated 
with methylating agent like N-methyl-N'-nitro-N-nitrosoguanidine, suggesting that 
MTB mounts an inducible response to methylating agents. Activity assays also 
disclose that both MTB AlkA and AdaB/OGT possess methyltransferase activity 
but not DNA glycosylase activity. Furthermore, the MTB AdaB/OGT expression in 
an E. coli Ada-OGT double-mutant, suppresses the hyper-mutator phenotype 
displayed upon alkylating agents treatment, while an analogous trans-
complementation experiment using the MTB adaA-alkA gene does not produce the 
same effect. Collectively, these data indicate that MTB AdaB/OGT counteracts the 
mutagenic effect of O
6
-mG while MTB AdaA-AlkA removes methyl groups from 
innocuous methylphosphotriesters [40]. As a matter of clarity through the 
following of the text the MTB AdaB/OGT protein will be indicated as MtOGT. 




MtOGT, invariably to other micro-organisms, acts through a suicidal mechanism 
by performing the irreversible transfer of O
6
-alkyl group from the modified 
guanine to the strictly conserved cysteine residue within the protein active site 
(Cys
126
) leading to its permanent inactivation (figure 15) [58]. 
Interestingly, a number of geographically widely distributed MTB strains (like 
MTB W-Beijing strains and multi-drug resistant isolates) have been identified 
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which carry non-synonymous SNPs in their ogt genes [59,60]. These point-
mutations result in amino acid substitution at position 15 (MtOGT-T15S) or 
position 37 (MtOGT-R37L) of MtOGT, mapping at the poorly structurally 
conserved N-terminal domain of the protein. 
Several researchers proposed that a defective OGT could lead to an increased 
mutation frequency, conferring to the corresponding strain a better adaptability to 
the host [54,60]. 
Recently, the high resolution crystal structure of MtOGT and its mutated variant 
MtOGT-R37L, together with the biochemical analysis of highly homogeneous 
recombinant versions of MtOGT, MtOGT-T15S and MtOGT-R37L were reported 
by our laboratory [58]. 
 
Figure 15: Alkyltransfer reaction from O
6
-methylguanine to OGT active site cysteine residue 
[58] 
  Similar to structures of other prokaryotic [61-64] OGTs as well as of human AGT 
[65-68] in different liganded states, both MtOGT and MtOGT-R37L fold into a 
roughly globular molecular architecture built up by two domains connected by a 
long loop and ending in a 10-residue-long tail. The MtOGT N-terminal domain 
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consists of an anti-parallel three-stranded β-sheet and connecting loops sandwiched 
between a mainly randomly coiled region, containing a single helical turn at its 






Figure 16: Crystal structure of MtOGT. Shown are cartoon representations of the MtOGT 
structure, as observed from two different points of view. In both images, the N-terminal domain, the 
C-terminal domain, and the connecting loop are colored in green, gray, and magenta, respectively. 
The catalytic cysteine residue (Cys
126
) is invariably drawn as sticks. Functional element labeling and 
secondary structure element numbering appear in the image at the left and at the right, respectively. 
aa, amino acids [58]. 
The C-terminal domain adopts the typical all-α-fold and houses the highly 
conserved functional elements that previous biochemical and mutational studies  
demonstrated to be required to perform efficient catalysis: (i) the helix-turn-helix 
(HTH) motif, which is responsible for DNA binding at its minor groove and bears 
Arg
109
 acting as a temporary substitute for the modified base upon its flipping out 
from the regular base stacking; (ii) the “Asn hinge” building up one wall of the 
deep ligand binding cavity that accepts the modified base for repairing; (iii) the 
strictly conserved PCHR consensus motif surrounding the catalytic cysteine 
(Cys
126
); (iv) the active-site loop that participates in the correct positioning of the 
alkylated base inside the ligand binding pocket; and (v) the structurally conserved 
H6 helix that, by shielding the ligand binding cavity on the opposite side of the Asn 
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hinge, contributes essential residues for completing the modified-base bonding 
network (Lys
146
) (Figure 16) [64-67,69 ,70]. 
Biochemical studies of wild-type MtOGT and its MtOGT-T15S and MtOGT-
R37L versions, revealed that MtOGT-R37L displayed a ten-fold reduced affinity 
towards methylated double-stranded DNA (dsDNA) than the wild-type protein, 
although neither mutation affects the intrinsic alkyl-guanine-transferase reaction 







Figure 17: Schematic representation of the possible functional consequences of the 
replacement of Arg
37
 with Leu in MtOGT. (i) Direct interference in the dealkylation reaction; (ii) 
reduced capability of establishing protein-protein interactions and tight monomer packing during 
cooperative DNA binding; (iii) direct participation of Arg
37
 in DNA binding. The N-terminal 
domain, the domain-connecting loop, and the C-terminal domain of the wild-type protein are 
colored green, magenta, and white, respectively. The MtOGTR37L structure is uniformly rendered 
in red; the modeled dsDNA appears in yellow [58]. 
Interestingly, Arg
37
 seems to play a central role in coordinating a peculiar 
network of bonds established between the core β-sheets and the facing random coil 
of the N-terminal domain. This observation prompted us to propose three not 
mutually exclusive scenarios possibly explaining how the mutation of Arg
37
, which 
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maps far away from both the Cys
126
 and the currently identified DNA binding 
motifs could produce an impact on protein function. As shown in Figure 17, the 
R37L mutation could (i) induce conformational changes of the N-terminal random-
coiled region that can affect catalysis, (ii) alter the assembly of protein complexes 
at the damaged site during cooperative DNA binding, and (iii) impair an 
unexpected participation of the Arg
37
-bearing random coil to direct DNA binding 
[58]. 
Our most recent work [70] allowed us to discriminate between these hypotheses, 
since it led to the resolution of the crystal structure of MtOGT in complex with 
DNA that, together with the characterization of further structure-based designed 
mutants of MtOGT, adds novelty to the current description of this interesting class 
of proteins, as it will be described in the “Chapter 3” of my Thesis. 
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Outline of the Thesis 
A long history of co-evolution with the mankind makes MTB capable to deal with 
a plethora of physical and chemical stresses, and surviving and replicating within 
one of the most inhospitable cell of the body: the macrophage. 
Despite this remarkable adaptation to the human host, during its entire life MTB 
is exposed to DNA-damaging assaults, whose consequences on genome stability 
could compromise the establishing of the primary infection, the persistence of the 
bacilli inside the macrophages - mainly in a dormant state that contributes to escape 
the host’s immune system surveillance-, as well as the correct execution of the 
reactivation program at resuscitation, that promotes the transition from the latent 
and asymptomatic phase to the active and contagious stage of the TB disease. 
On the other end, the occurrence of new mutations inside the mycobacterial 
genomic DNA is considered the driving force to acquire new phenotypic traits, 
including specific drug resistance, for which horizontal gene transfer has rarely 
been documented. Therefore a sub-optimal DNA repair could result in the fixation 
of mutations that are compatible with the MTB life and that confer to the bacillus a 
superior adaptive capability under a positive selective pressure. Two main 
observations support this argument; first, inside the MTB genome, the level of 
sequence polymorphism of genes encoding DNA replication, recombination and 
repair functions is remarkably higher with respect to that of house-keeping genes. 
Secondly, a number of geographically widely spread MTB strains carry peculiar 
single-nucleotide polymorphisms in several DNA repair genes, leading to the 
hypothesis that the associated phenotypes, in principle more prone to cumulate 
gene mutations, could have represented a selective advantage to the corresponding 
strains during MTB evolution. 
Although the key role of DNA repair in MTB biology is well established, the 
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information about i) the actual contribution of each DNA repair pathway to the 
overall maintenance of the MTB genome integrity, ii) the cross-talk between the 
DNA repair systems and other machineries involved in MTB DNA metabolism, 
and iii) the reciprocal co-ordination of these activities during TB pathogenesis, is 
still somehow fragmentary. 
Consequently, the study of DNA repair proteins in MTB is crucial not only to 
understand their functioning at a molecular level, but also to evaluate their impact 
upon the TB infection process. 
This was the rationale of my PhD research activity, aimed at a better biochemical 
and structural description of proteins involved in alkylated-DNA repair in MTB, 
along with their interaction studies. The majority of living organisms deploy 
several strategies to defend their genome from the genotoxic and pro-mutagenic 
potential associated to DNA alkylation, including i) the direct reversal of the 
damage, through the one-step, irreversible and suicidal action of an alkylated 
DNA-protein alkyltransferase, such as OGT (also known as MGMT or AGT in 
other species including humans), and ii) the multistep excision of a short 
oligonucleotide containing the lesion, followed by DNA new synthesis (NER 
system). 
My Thesis focuses on the MtOGT protein and on its possible interaction with the 
MtUvrA component of the lesion-sensing complex of the NER. 
As detailed in Chapter 3, I participated to the determination of the crystal 





double-stranded DNA molecule, which acts as a mechanistic inhibitor of the 
protein by irreversibly binding the C-terminal catalytic domain. The structural 
analysis of such a complex, together with the biochemical characterization of a 
restricted panel of MtOGT mutated variants, allowed us to describe peculiar 
features of the mycobacterial protein compared to the pre-existing information on 
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members this protein family. Indeed, in our structure, we directly observed for the 
first time the mode of assembling of three MtOGT monomers to the same E1X-
dsDNA molecule. This arrangement discloses details of the protein-protein and 
protein-DNA interactions sustaining the cooperative DNA-binding mechanism of 
MtOGT. Another element of novelty is represented by the capability of the two 
protein monomers that are not engaged in binding the E1X base, to host an 
unmodified adenine in their active site, contributing further information to build a 
model of the alkylation damage detection process. Finally, we observed that 
discrete regions of both the N- and the C-terminal domains of MtOGT display a 
high level of structural plasticity, a specific feature of the mycobacterial protein. 
Interestingly, several frequently isolated MTB strains contain a non-synonymous 
SNP in their OGT-encoding gene that leads to the substitution of the Arginine 
residue at position 37 (Arg
37
) by a Leucine. Former studies at our research Unit 
revealed that a recombinant version of this mutated MtOGT variant (MtOGT-
R37L) was impaired in catalysis, showing a 10-folds lower affinity for methylated 
DNA (see the Introduction). The results of the present work suggest that Arg
37
 
could impose some restrictions to the structural flexibility of the N-terminal 
domain random coiled region, thus representing a plausible determinant of the 
optimal protein assembling at the alkylated site during DNA recognition and repair. 
 In the “Unpublished Results” section (Chapter 4) of my Thesis, I reported the 
still ongoing investigations aimed at characterizing a possible cross-talk between 
OGT-mediated alkylated-DNA repair and the NER system, pivoting on an 
unprecedented interaction between MtOGT and MtUvrA. The formation of 
MtUvrA::MtOGT complex was disclosed in the context of high throughput 
screenings of protein-protein interactions in mycobacteria (liquid chromatography-
based affinity purification coupled with high resolution mass spectrometry), and 
found a preliminary confirmation in Surface Plasmon Resonance (SPR)-based 
interaction studies. To isolate and characterize the MtUvrA::MtOGT complex, I 
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performed size-exclusion chromatography-based co-fractionation experiments, 
using the recombinant pure proteins, including the well-known protein partner of 
MtUvrA, i.e. MtUvrB. These analyses will aid us to better define the experimental 
setting to adopt in the future to further describe macromolecular interactions 
sustaining alkylated DNA repair in MTB. 
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-methylguanine-DNA methyl-transferase (MtOGT) 
contributes to protect the bacterial GC-rich genome against the pro-mutagenic 
potential of O
6
-methylated guanine in DNA. Several strains of M. tuberculosis 
found worldwide encode a point-mutated O
6
-methylguanine-DNA 
methyltransferase (OGT) variant (MtOGT-R37L), which displays an arginine-to-
leucine substitution at position 37 of the poorly functionally characterized N-
terminal domain of the protein. Although the impact of this mutation on the 
MtOGT activity has not yet been proved in vivo, we previously demonstrated that a 
recombinant MtOGT-R37L variant performs a suboptimal alkylated-DNA repair in 
vitro, suggesting a direct role for the Arg
37
-bearing region in catalysis. The herein 
reported crystal structure of MtOGT complexed with modified DNA reveals details 
of the protein–protein and protein–DNA interactions occurring during alkylated-
DNA binding, and the protein capability also to host unmodified bases inside the 
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active site, in a fully extrahelical conformation. Our data provide the first 
experimental picture at the atomic level of a possible mode of assembling three 
adjacent MtOGT monomers on the same monoalkylated dsDNA molecule, and 
disclose the conformational flexibility of discrete regions of MtOGT, including the 
Arg
37
-bearing random coil. This peculiar structural plasticity of MtOGT could be 
instrumental to proper protein clustering at damaged DNA sites, as well as to 
protein–DNA complexes disassembling on repair. 





Mycobacterium tuberculosis displays a remarkable genetic stability despite the 
continuous exposure to potentially promutagenic and genotoxic stresses that could 
compromise the pathogen’s capability of establishing a latent infection in the 
human host and exiting from the dormant state at reactivation [1,2]. Generated by 
the M. tuberculosis-infected macrophages as part of the antimicrobial response, 
highly reactive oxygen and nitrogen intermediates can directly damage several 
mycobacterial targets, including DNA, and can trigger the endogenous synthesis of 
potent DNA-alkylating metabolites [3-5]. 
As observed in other organisms, M. tuberculosis repairs alkylated bases in DNA 
either by using multi-enzymatic systems or through the action of single proteins 
[6,7], such as the O
6
-methylguanine-DNA methyltransferase (OGT, EC: 2.1.1.63). 
Genes encoding O
6
-alkylguanine-DNA alkyltransferases (alternatively abbreviated 
as AGT or MGMT) have been identified in the genome of the most diverse 
organisms, and numerous studies aimed at the functional characterization of 
members of this protein family have been published (reviewed by Pegg [8,9]. 
These analyses reveal that alkyltransferases preferentially repair O
6
-alkylated 
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guanine in DNA, invariably performing the stoichiometric transfer of the alkyl 
group from the modified base to a conserved cysteine residue buried in their active 
site [10-12]. Much less is known about the cellular fate of the inactivated protein 
resulting from DNA repair, although it has been proposed that the irreversible 
alkylation of the catalytic cysteine could induce conformational changes, which 
might increase protein instability in vitro and its propensity to degradation in vivo 
[13,14]. 
The M. tuberculosis OGT (MtOGT)-encoding gene is part of the mycobacterial 
adaptive response operon [15], and evidence was obtained pointing at MtOGT as a 
main player in protecting the M. tuberculosis chromosome against the risk of G:C-
to-A:T transition mutations associated with O
6
-alkylated guanine in DNA 
[3,6,16,17]. It is interesting that a number of geographically widely distributed M. 
tuberculosis strains and multidrug-resistant isolates are characterized by point-
mutated OGTs carrying an amino acid substitution at position 15 or 37 of the N-
terminal domain (T15S and R37L), and it has been proposed that a defective 
alkylated-DNA repair could have played a role in tuning the balance between 
genome stability preservation and adaptability to the host during the evolutionary 
history of the pathogen [18-20]. Although the functional consequences of the 
presence of these MtOGT variants on the biology of the corresponding strains have 
not yet been determined, we showed that a recombinant MtOGT-R37L is 
significantly impaired in alkylated-DNA damage reversal in vitro, displaying a 10-
fold lower affinity for methylated dsDNA (dsDNA
met
) with respect to the wild-type 
protein [21]. 
Parallel X-ray crystallography studies of the ligand-free form of MtOGT showed 
that Arg
37
 belongs to a mainly random coiled region (residues 28–47) of the N-
terminal domain, the sequence and overall structure of which significantly vary 
among OGTs from different species [21]. Moreover, Arg
37
 maps away from the 
protein active site and the DNA-binding motifs so far identified, based on structural 
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analyses of the human orthologue O
6
-alkylguanine-DNA alkyltransferase (hAGT) 
[22-25]. Finally, the structural comparison of MtOGT and MtOGT-R37L showed 
that the Arg
37
-to-Leu substitution produces a negligible impact on the protein 
conformation in the absence of ligands [21], underlining the need to obtain the 
structure of MtOGT in alternative substrate-bound states in order to elucidate the 
molecular determinants of the observed suboptimal catalysis performed by the 
MtOGT-R37L variant. 
In the present study we describe the crystal structure of wild-type MtOGT 







containing dsDNA (MtOGT::E1X-dsDNA), which reveals similar as well as 
peculiar traits when compared with the equivalent structure of human AGT [24]. 
Indeed, in the MtOGT::E1X-dsDNA structure, we directly observed, for the first 
time, a possible mode of assembling three adjacent protein chains on to the same 
damaged DNA duplex. This allowed us to gain insight into the architecture of 
protein–DNA complexes that could explain the cooperative DNA-binding 
mechanism of MtOGT, which was suggested by EMSA-based analyses [21] and 
the present study. It is interesting that, in the MtOGT::E1X-dsDNA structure, the 
protein monomers that are not engaged in binding the modified base are equally 
observed to host an unmodified adenine in their active site, contributing further 
information to the vision of a mechanistic model of the alkylation damage 
detection process. Finally, discrete regions of both the N- and the C-terminal 
domains of MtOGT display a high level of structural plasticity, a specific MtOGT 
feature that could be required for proper protein assembly at the alkylated site 
during DNA repair, as also suggested by the biochemical and structural 
characterization of additional MtOGT mutated variants. 
 
 





All reagents were obtained from Sigma-Aldrich unless otherwise specified. 
Expression and purification of point-mutated MtOGT variants 
The pET-MtOGT construct coding for the wild type MTB O
6
-methylguanine 
methyltransferase (orf: Rv1316c) [21] was used as the DNA template in PCR-
based site-directed mutagenesis experiments, using the QuikChange II site-directed 
mutagenesis kit reagents (Stratagene) and the primer pairs R37K5´/R37K3´, or 
R37E5´/R37E3´, or Y139F5´/Y139F3´ (Supplementary Table 1). The region 
encoding the corresponding point-mutated MtOGT variant in each resulting 
expression construct (namely pET-MtOGT-R37K, pET-MtOGT-R37E and pET-
MtOGT-Y139F) was verified by sequencing (Eurofins MWG Operon). The 
expression and purification of the three new point-mutated versions of MtOGT 
used in crystallization trials and activity assays were achieved by adopting the same 
procedure used for the wild-type protein [21]. All proteins are monomeric and 
display similar stability in solution (not shown). 
Synthesis of the E1X-containing oligonucleotide 
The E1X monomer [26] was prepared adopting the reaction scheme illustrated in 
Supplementary Figure S1. The full procedure used for the synthesis of the E1X-
modified oligonucleotide (ON473 in Supplementary Table S1 and Supplementary 
Figure S2) appears in the Supplementary Methods section. The ON473 
oligonucleotide was annealed to 1.2 molar equivalents of the complementary strand 
(anti-ON473 in Supplementary Table S1) in 20 mM Tris/HCl, pH 7.5, and 25 mM 
NaCl, resulting in the E1X-dsDNA used in crystallization trials. 
Crystallograpic studies 
Crystallization 
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Wild-type MtOGT was purified as previously described [21], with buffer 
exchanged against 20 mM Tris/HCl, pH 7.5, and 25 mM NaCl (PD10 column, GE 
Healthcare), mixed with E1X-dsDNA in equimolar ratio, and incubated for 18 h at 
4 
◦
C. The reaction mixture was concentrated (10-kDa MWCO, Vivaspin, 
Vivascience, Fisher Scientific) and loaded on to a size exclusion chromatography 
column (Superdex 200 10/300, GE Healthcare). The MtOGT::E1X-dsDNA 
complexes eluted in a broad peak corresponding to absorption maxima at 
wavelengths 280 nm and 260 nm; the corresponding fractions were pooled, and 
concentrated up to 5 mg/ml as described above. Crystallization conditions for the 
MtOGT::E1X-dsDNA complex were identified by means of a robot-assisted 
(Oryx4, Douglas Instruments), sitting drop-based, spare-matrix strategy using kits 
from Hampton Research and Qiagen. The initially obtained needle clusters were 
used as micro-seeds to inoculate 1 μl of freshly prepared MtOGT::E1X-dsDNA 
complex mixed with an equal volume of reservoir solution (0.2 M ammonium 
acetate, 22 % PEG 3350 and 0.1 M Hepes, pH 7.5), and equilibrated in a hanging 
drop against 800 μl of the reservoir solution at 4 
◦
C. Single thin rod crystals grew 
up to their maximum dimensions of 0.05 mm in about 6 weeks. Crystals of the 
R37K or Y139F MtOGT variants were grown using the hanging drop vapour 
diffusion method by mixing 2 μl of the corresponding protein solution at 5 mg/ml 
with an equal volume of a reservoir solution containing 0.1 M Hepes, pH 7.5, 4 % 
PEG 8000, and either 4 % or 8 % ethylene glycol (for MtOGT-R37K and MtOGT-
Y139F, respectively); the drops were equilibrated against 800 μl of the 
corresponding reservoir solution at 4 
◦
C until crystals reached their maximum 
dimensions of 0.2 mm in about 2 weeks. 
Data collection 
All crystals used in diffraction experiments were directly taken from the 
corresponding crystallization drop, rapidly equilibrated in the specific reservoir 
solution containing 15 % glycerol as cryoprotectant, and flash-frozen under liquid 
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nitrogen. Diffraction experiments were conducted at 100K using synchrotron 
radiation at the ID-29 (MtOGT::E1X-dsDNA complex) or ID14-EH4 (MtOGT-
R37K and MtOGT-Y139F variants) beam lines (European Synchrotron Radiation 
Facility, Grenoble, France). Complete diffraction datasets were collected up to 3.0-, 
2.3-and 2.6-Å resolution (1 Å = 0.1 nm) for crystals of the MtOGT::E1X-dsDNA 
complex, and the MtOGT-R37K and the MtOGT-Y139F variants, respectively. For 
all data collections, diffraction intensities were integrated and scaled by using the 
CCP4 suite of programs [27]. 
Structure determination 
Analysis of the MtOGT::E1X-dsDNA diffraction dataset assigned the crystal to the 
orthorhombic space group P212121, with cell dimensions a = 43.48 Å, b = 102.90 Å 
and c = 137.09 Å, containing three protein chains and one dsDNA molecule per 
asymmetrical unit, with a corresponding solvent content of 50 %. The structure of 
the MtOGT::E1X-dsDNA complex was solved by molecular replacement using the 
program Phaser [28]. The starting search model for the protein component was the 
structure of MtOGT (PDB accession code 4BHB) [21], edited to omit the Tyr
139
 
residue of the active site loop and the C-terminal tail (residues 156–165); the 
starting search model for the DNA component was the E1X-dsDNA, as crystallized 
in complex with hAGT (PDB accession code 1T39) [24], omitting bases 12–13 and 
14–15 of the duplex. The resulting electron density map was of good quality, 
allowing manual model rebuilding, using the program Coot [29]. The program 
PHENIX [30] and Refmac [27] were used for crystallographic refinement and to 
add water molecules. The structures of MtOGT-R37K and MtOGT-Y139F were 
solved by molecular replacement using the program Phaser [28] and the structure 
of wild-type MtOGT as the search model (PDB accession code 4BHB) [21], 




 residues, respectively. 
In both cases the procedure yielded high-quality electron density maps. Manual 
model building, crystallographic refinement and solvent addition were performed 
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as described above for the MtOGT::E1X-dsDNA structure. The stereochemistry of 
the refined models has been assessed using the program PROCHECK [31]. Data 
collection and refinement statistics are summarized in Table 1. Structural 
superimpositions were performed with the Superpose program of the CCP4 suite 
[27]; figures were generated using PyMol [32]. 
 
Deposition 
The atomic coordinates and structural factors of the MtOGT::E1X-dsDNA 
complex, MtOGT-R37K and MtOGT-Y139F have been deposited in the Protein 
Data Bank(http://www.rcsb.org) under the PDB accession codes 4WX9, 4WXC 
and 4WXD, respectively. 
Biochemical analyses 
To measure the alkyltransferase activity of the new MtOGT point-mutated variants. 
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MtOGT-R37K, MtOGT-R37E and MtOGT-Y139F, competitive assays using the 
fluorescent SNAP-Vista Green reagent (VG; New England BioLabs) were 
performed as previously described [21,33]. Similarly, the EMSA-based analysis of 
the three mutated variants of MtOGT was performed adopting the same protocol 




Overall structure of MtOGT complexed with E1X-dsDNA 
In order to clarify the functional role of the Arg
37
 in MtOGT-mediated catalysis, we 
co-crystallized the wild-type protein in the presence of the 13-bp-long E1X-
dsDNA, thus choosing the same experimental strategy first adopted by Daniels et 
al. [24] to solve the structure of wild-type hAGT covalently bound to a modified-
dsDNA (PDB code 1T39). Different from the equivalent structure of the human 
enzyme, in the MtOGT::E1X-dsDNA crystal structure, three protein chains (A, B 
and C) and one E1X-dsDNA molecule are present in the asymmetrical unit, with 
chain A binding the E1X base at position 7 of the modified strand (E1X7 ) (Figure 
1a). It is of interest that, by applying crystallographic symmetry operators, a 
peculiar supramolecular assembly can be observed in the MtOGT::E1X-dsDNA 
crystal lattice (Figure 1b). By focusing on a unit consisting of chain A bound to the 
E1X7 base, and counting nitrogenous bases starting from the 5
´
-end of each strand, 
a symmetry equivalent of chain C (‘C sym. mate’) binds the deoxyadenosine 
residue at position 4 of the modified strand (dA4), and a symmetry equivalent of 
chain B (‘B sym. mate’) does the same with the deoxyadenosine residue at position 
5 of the complementary strand (dA18). In all cases, the bound base adopts a fully 
extrahelical conformation, and is deeply inserted into the protein active site. 
Overall, the MtOGT::E1X-dsDNA complex can be described as consisting of two 
co-oriented MtOGT monomers sharing 1 bp of their 4-bp-long DNA-anchoring site 
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on the damaged strand and displaying a reciprocal ‘N-to-C’ domain arrangement 
(‘chain A’ and ‘C sym. mate’), whereas the third chain (‘B sym. mate’), which 
binds the intact strand, shows a ‘C-to-C’ domain arrangement with respect to chain 
A (Figure 1c). 
 
Figure 1: The overall structure of MtOGT complexed with modified DNA 
(a) Cartoon representation of the asymmetrical unit content of the MtOGT::E1X-dsDNA crystal; the 
E1X-containing dsDNA is observed complexed with chain A, the C-terminal domain of which hosts 
the modified base (E1X, red arrowhead). (b) Cartoon representation of three MtOGT chains 
assembled on to the same E1X-dsDNA molecule, resulting from applying crystal symmetry 
operators; extrahelical bases are rendered as sticks and signalled by an arrowhead (inset: zoomed 
view of the contact region between the co-oriented chains that bind bases of the modified DNA 
strand). (c) Representation of the reciprocal arrangement of the protein chains and DNA duplex 
illustrated in (b); the dashed arrow points to a scheme of the covalent adduct formed between the 
chain A catalytic cysteine (Cys
126
) and the E1X base. The colour codes for protein domain and 
DNA strand identification appear at the bottom of the figure. 
The association of each MtOGT chain on to the E1X-dsDNA molecule is mainly 
stabilized by the strong protein–DNA interactions established by the helix-turn-
helix (HTH) motif and a few conserved active site residues of each subunit, with 
the DNA minor groove and the flipped base, respectively (see below). In contrast, 
protein–protein interchain contacts are limited to a weak interaction engaging the 
co-oriented monomers ‘chain A’ and ‘C sym. mate’ (Figure 1b, inset). However, it 
must be noticed that, different from the crystal structures of wild-type MtOGT and 
point-mutated variants of the protein in their ligand-free forms [21] (and the present 
study), in the MtOGT::E1X-dsDNA structure no electron density was visible for 
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chain A residues 33– 35 (omitted from the final model), and a poor electron density 
characterizes region 29–36 of the N-terminal domain random coil in each chain. 
For this reason, we cannot assume, under physiological conditions, that a higher 
number of contacts are established between the MtOGT chain binding the alkylated 
base and the adjacent protein subunit locking the unmodified base at 4 bp upstream 
to the lesion (‘chain A’ and ‘C sym. mate’ in Figure 1). 
The structure of the MtOGT active site complexed with E1X-dsDNA 
Ground-breaking X-ray crystallography-based studies on recombinant versions of 
hAGT complexed with modified dsDNA, containing either a physiologically 
relevant O
6
-methylguanine residue [24] or base analogues carrying bulky 
substituting groups [24,25], disclosed the molecular details of the protein 
association with alkylated DNA. These results showed that hAGT invariably binds 
the dsDNA substrate at the level of its minor groove, by exploiting the conserved 
HTH motif of the protein C-terminal domain. In this peculiar mode of protein–
dsDNA assembly, the modified nitrogenous base is flipped out from the regular 
base stacking and clamped into the enzyme active site pocket, thus resulting in 
proper placement of the reactive cysteine (Cys
145
 in hAGT) to catalyse the SN2-like 
dealkylation reaction [24,25]. 
The architecture of the substrate-binding site of the three MtOGT chains building 
up the MtOGT::E1X-dsDNA crystal structure is quite similar to the one described 
for the human orthologue complexed with different dsDNA species (Figure 2a). 
Inspection of the active site of MtOGT chain A reveals a continuous density signal 
contouring the catalytic Cys
126
 and the modified E1X7 base (Figure 2b). Other 
close protein–DNA contacts involve: the strictly conserved ‘arginine finger’ 
(Arg
109
) which, by invading the double helix from the minor groove side, and 
stacking between the planes of the dG6 and dC8 bases, structurally compensates for 
the flipped-out E1X7 base; the carboxamide group of Asn
115
, observed at a 2.9-Å 
mean distance from the E1X7 O
2
 position; the hydroxyl group of Tyr
95
, standing at 
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a 3.4-Å mean distance from both the N
3
 atom and the deoxyribose moiety of the 




, the backbone oxygen 





, respectively; and Tyr
139
 which contributes to narrowing of the active 
site and increasing the aromatic nature of the ligand-binding pocket. In addition, 
the positive charge at the N-side of helix H3 and the main-chain nitrogen atom of 
Ala
132
 appear to lock, from both sides, the sugar–phosphate backbone downstream 
of the lesion (Figure 2c). 
 
Figure 2: Structural analysis of the MtOGT protein complexed with E1X-dsDNA 
(a) Cartoon representation of the optimally superimposed structures of MtOGT (chain A) and hAGT 
(pdb code 1T39), each in complex with the E1X-dsDNA substrate; the E1X base is rendered as 
sticks and coloured, applying the same colour codes used for the corresponding protein chain 
(shown on the top of the panel). (b) Close-up view of the active site of the MtOGT::E1X-dsDNA 
chain A housing the modified base (E1X7), with σA-weighted 2Fo − Fc electron density contoured 
at 1.0 σ; the Cys
126
 thiol group is observed at a distance of 2.1A° from E1X7, the C11 atom; the 
protein backbone appears as a ribbon. (c) Zoomed view of the MtOGT chain A active site 
complexed with E1X-dsDNA; secondary structural elements and functional motifs are indicated in 
italic (the colour codes for protein domain/DNA strand identification appear in panel a). (d) Cartoon 
representation of the active site of optimally superimposed MtOGT::E1X-dsDNA chains A, B and C 
(average RMSDs are 0.671 and 0.456A° for the couples B/A and C/A, respectively); DNA appears 
as a cartoon and coloured, applying the same colour codes used for the corresponding protein. 
Protein residues and DNA bases mentioned throughout the text are rendered as sticks. 




With the obvious exception of contacts involving E1X7-specific positions, an 
almost identical bonding scheme is observable in the active site of chains B and C 
– which host the symmetry equivalent of the dA18 and dA4 unmodified bases, 
respectively (Figure 2d) – thus indicating that MtOGT can efficiently bind 
nitrogenous bases independently of the presence of the alkyl adduct. 
In principle, the insertion of an undamaged adenine residue into the MtOGT 
ligand-binding pocket would not expose the DNA substrate to an increased risk of 





positions – as they were observed in the active site of the B and C chains of the 
MtOGT::E1X7-dsDNA structure – does not appear significantly enhanced by the 
nearby catalytic cysteine, nor by the presence of the other residues coordinating the 
base (see Supplementary Figure S3a). 
Notably, one of the three protein chains (chain hAGT-B) building up the crystal 
structure of hAGT in complex with a dsDNA containing an N
4
-alkylcytosine base 
(PDB code 1YFH) [25] binds the thymine base at the 3´-end of the modified strand. 
However, different from what we observed in the active site of the B and C 
monomers of the MtOGT::E1X-dsDNA structure, the thymine base appears to be 
only partially inserted into the hAGT-B ligand-binding pocket (see Supplementary 
Figure S3b). We therefore speculated that MtOGT could perform lesion searching 
through a non-selective base-flipping mechanism, with the flipped-out base fully 
inserted into the active site. If this assumption is correct, MtOGT could not adopt a 
gate-keeping mechanism in discriminating between normal and damaged bases in 
vivo, different from what was hypothesized for the human counterpart [25,34]. 
MtOGT undergoes structural rearrangements on DNA binding 
The structure of MtOGT complexed with E1X-dsDNA discloses a further unique 
feature of the mycobacterial protein, i.e. its conformational plasticity. In fact, the 
structural analyses of hAGT [22,23,24,25] and Solfolobus sulfataricus OGT [35], 
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at different stages of the transalkylation reaction, suggest that the active site of the 
human and archaea proteins is largely pre-shaped to perform the catalysis, without 
requiring heavy structural rearrangements. On the contrary, the association of 
MtOGT with the E1X-dsDNA substrate induces the repositioning of three solvent-
exposed protein regions: a random coiled segment (residues 29–39) of the N-
terminal domain, part of the active site loop (residues 135–142) and the C-terminal 
tail (residues 156–165) (Figure 3a). As a consequence, each protein monomer in 
the MtOGT::E1X-dsDNA complex appears more compact than the ligand-free 
protein (Figure 3b). These conformational changes are accompanied by the side-
chain repositioning of a number of residues of both protein domains (Figure 3c). It 
is interesting that, in the MtOGT::E1X-dsDNA structure, the segment 
encompassing residues 29–35 moves away from the three-stranded β -sheet that 
builds up the core of the N-terminal domain, and gets closer to the DNA-binding 
surface of the C-terminal domain, behaving as a flap that sees Arg
37
 as its pivotal 
point. 
We underline that this analysis was mainly conducted by inspecting the 
conformation adopted by chains B and C, because, different from chain A, their α-
carbon backbone at the level of the flap is fully defined. However, given the 
minimal average RMSD resulting from superimposing the three protein chains 
building up the MtOGT::E1X-dsDNA crystal structure, and taking into account that 
the B and C monomers host a nitrogenous base in their active site (see Figure 2d), 
we propose that an equivalent structural repositioning of the flap might also occur 
in the MtOGT subunit binding the modified base. 
The Arg
37
-containing random coil could participate in the cooperative 
assembly of protein clusters on to the dsDNA substrate 
The analysis of the MtOGT::E1X-dsDNA crystal structure seems to exclude direct 
participation of Arg
37
 in DNA binding, because the protein residue and the sugar–  




Figure 3: The conformation adopted by discrete protein regions differs in the ligand-free and 
DNA-bound MtOGT structures 
(a) Structural superposition of MtOGT in its apo form (PDB code 4BHB, green coloured) and 
complexed with E1X-dsDNA (PDB code 4WX9), highlighting the main structural rearrangements 
characterizing the DNA-bound chain A (in white) and chain C (in violet). (b) Surface representation 
of a MtOGT monomer in ligand-free and DNA-bound states; the arrows indicate the direction of the 
movements of the flap (1), the active site loop (2) and the tail (3) of the protein on DNA binding. (c) 
Zoomed views of selected residues, with a side-chain conformation that differs between the 
superimposed structures of ligand-free (upper panel) and E1X-dsDNA-bound (lower panel) 
MtOGT. 
phosphate backbone of the E1X-dsDNA substrate are observed at a distance of >16 
Å (Figure 3a). Instead, we propose that Arg
37
 could function as a hinge limiting the 
conformational plasticity at the C-side of the flap, by participating to keep it in 
contact with the bulk core of the N-terminal domain, and also on the formation of 
the protein–DNA complex (Figure 3c). In principle, the absence of such an 
anchoring site – as exemplified by the MtOGT-R37L variant characterizing a 
number of frequently isolated M. tuberculosis strains – could affect the capability 
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of the flap to undergo discrete movements. In turn, the resulting unrestrained 
flexibility of the N-terminal domain random coil could hamper the correct 
assembly of MtOGT clusters at the damaged DNA sites. 
To test this hypothesis, we expressed and purified two new mutated versions of 
MtOGT (MtOGT-R37K and MtOGT-R37E), and analysed their dsDNA
met
-
repairing activity, by adopting the same VG-based assay [33] previously used to 
characterize the wild-type protein and the MtOGT-R37L variant [21]. Our data (see 
Supplementary Table S2) show that the MtOGT-R37E mutant exhibits a 5-fold 
lower affinity for the methylated duplex (KDNA
met
 R37E = 1.14 ± 0.15µM) with 
respect to MtOGT (KDNA
met
 wt = 0.24 ± 0.11µM [21]), whereas the more 
conservative Arg
37





 R37K = 0.38 ± 0.2 µM). 
In parallel we perform EMSA-based experiments (Figure 4a) using TAMRA 
(tetramethylrhodamine)-labelled non-alkylated dsDNA probe (see Supplementary 
Table S1). It is interesting that the MtOGT-R37E protein reaches a plateau in band-
shift activity at a DNA:protein molar ratio of 1:600 (KDNA
met
 R37E = 41.4 ± 1.1 µM), 
whereas both the wild-type MtOGT and the MtOGT-R37K induce a complete shift 
at DNA:protein molar ratio of 1:150 (KDNA-wt = 7.2 ± 0.2µM [21], KDNA-R37K = 13.2 
± 0.7 µM). The results of the EMSA-based analysis well with those obtained from 
the VG-based competitive assays, and are consistent with previously published data 
showing that the recombinant MtOGT-R37L variant displays a 10-fold lower 
affinity towards the dsDNA
met
 substrate compared with the wild-type MtOGT, 
although the cooperativity of DNA binding is maintained [21]. Taken together, our 
past studies [21] and the present study confirm that the Arg
37
 residue, although not 
being directly involved in substrate binding, plays an active role during catalysis, a 
role that can be performed almost equally well by the positively charged lysine 
residue. By contrast, the presence of a hydrophobic or negatively charged side 
chain at position 37 of the MtOGT protein – which characterizes the MtOGT-R37L 
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and MtOGT-R37E proteins, respectively – translates into less efficient DNA 
binding and repair. 
 
Figure 4: A positively charged residue at MtOGT position 37 is required for optimal dsDNA 
binding 
(a) Upper image: EMSA-based analysis of wild-type MtOGT (WT) [21], and of the indicated point-
mutated proteins, performed by using 1 pmol of TAMRA-labelled dsDNA (see Table 1) as the 
probe (DNA); lanes 2–9: increasing amounts of protein (P) incubated in the presence of the probe at 
the indicated DNA:protein molar ratio; in each panel the open arrowheads point to the shifted DNA 
probe. Lower image: plot of the DNA-bound protein fraction at each DNA:protein molar ratio tested 
in EMSA (upper image); [P], protein concentration (M); K , dissociation constant (μM). (b) Close-
up of the N-terminal domain and part of the of the active site of the ligand-free MtOGT (PDB code 
4BHB) [21] and MtOGT-R37K (PDB code 4WXD), on optimal structural superimposition; residues 
mentioned in the text appear as sticks; secondary structure elements are labelled in italic. 
By analyzing the crystal structure of the MtOGT-R37K variant (Figure 4b and see 
Table 1), we noticed that the lysine residue could partially substitute for arginine, 
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in terms of charge and size, inside the peculiar network of contacts established 
between the second β -strand and the facing random coiled region of the N-terminal 
domain. In the structure of the loss-of-function MtOGT-R37L protein, the presence 
of a leucine at position 37 destroys this bonding scheme [21]. However, in both 
these ligand-free structures, no relevant changes of the local fold are observable. 
Given the requirement of a positively charged group at position 37 of the protein 
for a fully efficient catalysis, we speculate that Arg
37
 could play a role in 
coordinating the repositioning of the flap during proper DNA recognition and 
binding, thus optimizing molecular contacts between adjacent monomers 
assembled on to the damaged DNA, as observed in the MtOGT::E1X-dsDNA 
structure. 
The intrinsic flexibility of the MtOGT active site loop 
As mentioned above, the active site loop and the C-terminal tail of MtOGT adopt 
different conformations, depending on the association of the protein with the DNA 
substrate (see Figure 3). Different from what has been reported for all OGTs for 
which the crystal structure has so far been solved [22-25,35-37], but reminiscent of 
what was observed in the OGT structure of Methanococcus jannaschii in solution 
[38], the C-side region of the active site loop (residues 136–141) of the ligand-free 
structures of MtOGT and its mutated variants is invariably oriented towards the 
bulk solvent. This conformation is stabilized by contacts established between the 
Tyr
139
-conserved residue of the active site loop and the stretched-out C-terminal 
tail of the closest symmetry mate within the crystal lattice [21] (and the present 
study). On the contrary, the C-side of the active site loop of each protein chain that 
builds up the MtOGT::E1X-dsDNA structure is bent inwards towards the catalytic 
pocket, where it participates in making the ligand-binding cavity fit the flipped-out 
base (Figure 5a). These observations raise the possibility that the active site of 
MtOGT could exist in two alternative conformations (‘ligand-free/active site loop 
out’ or ‘DNA-bound/active site loop in’) also in a physiological context, displaying 
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a degree of structural plasticity higher than that characterizing the equivalent region 
of hAGT. 
However, if the Tyr
139
 residue of the active site loop of MtOGT performed 
exactly the same molecular tasks highlighted for the equivalent residue of the 
human protein (Tyr
158
), namely narrowing of the ligand-binding pocket and 
providing an aromatic environment for the alkyl adduct [24,25], then the 
substitution of Tyr
139
 by a phenylalanine should have little effect on catalysis. 
Data from VG-based assays (see Supplementary Table S2) reveal that a MtOGT-
Y139F variant displays a 10-fold lower affinity for dsDNA
met
 compared with wild- 
type MtOGT (KDNA
met
Y139F = 2.19±0.5 μM; KDNA
met
wt = 0.24±0.11 μM [21]), 
confirming the MtOGT requirement of a tyrosine residue at position 139 for 
optimal repair of an O
6
-methylated guanine in dsDNA. Instead, the MtOGT ability 
to bind unmodified dsDNA appears less affected by the Tyr
139
-to-Phe substitution; 
in fact, when analysed in EMSA, both proteins reach a plateau in band-shift 
activity at a DNA:protein molar ratio of approximately 1:150, displaying an 
affinity towards the unmodified probe that differs 3-fold (KDNA-wt = 7.2±0.2 μM 
[21], KDNA-Y139F = 20.5±3.2 μM; Figure 5b). Therefore, we speculate that Tyr
139 
could play a role not only in properly fixing the base inside the protein active site 
on DNA binding, as proposed for hAGT Tyr
158
 [24,25,39-41], but also in making 
MtOGT able to discriminate between intact and alkylated dsDNA molecules, albeit 
through a molecular mechanism that will need further study for elucidation. 
The MtOGT::E1X-dsDNA crystal structure provides insights into cooperative 
DNA binding 
The architecture of MtOGT in a stable complex with the E1X-dsDNA substrate 
could be regarded as a snapshot of a potential reaction step at which the modified 
base has already been recognized and bound by one monomer (chain A), whereas 
two other subunits (the chain B and C symmetry mates) occlude available binding  



















Figure 5: The Tyr
139
 residue could help the active site loop movements during DNA binding 
 (a) Zoomed view of the active site of MtOGT (PDB code 4BHB) [21] and MtOGT-Y139F (PDB 
code 4WXC) – both crystallized in ligand-free form – and of the A, B and C chains building up the 
MtOGT::E1X-dsDNA complex (PDB code 4WX9), resulting from optimal superimposition of the 
corresponding structures (colour codes for protein/chain identification appear on the right); residues 
mentioned in the text appear as sticks; secondary structure elements are labeled in italic. (b) Upper 
image: EMSA-based analysis of MtOGT (WT) [21] and its Y139F mutated variant, performed as 
detailed in Figure 4. Lower image: plot of the DNA-bound protein fraction at each DNA:protein 
molar ratio tested in EMSA (upper image); [P], protein concentration (M); K , dissociation constant 
(μM). 
sites on both strands of the dsDNA substrate, at the highest possible density 
allowed in the close proximity of the lesion, by housing unmodified nucleobases in 
their active site (see Figure 1). From this standpoint, the supramolecular assembly 
revealed by our structure could represent a model of the MtOGT clustering on a 
monoalkylated dsDNA molecule. 
However, we cannot rule out the possibility that longer, more physiological DNA 
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substrates might sustain the nucleation of MtOGT protein clusters larger in size 
than the one characterizing the MtOGT::E1X-dsDNA crystal structure. To verify 
this hypothesis, we tried to model further DNA-bound MtOGT monomers towards 
the 5
´
-end of the modified strand, starting from the experimental ‘C sym. mate’ 
(monomer ‘2’ in Figure 6), and using the ‘chain A/C sym. mate’ dimer as the 
moving unit (monomers ‘1’ and ‘2’ in Figure 6). 
It is of interest that the unprecedented association of a MtOGT monomer with the 
region of the intact DNA strand facing the alkylated base (i.e. the ‘B sym. mate’-
binding dA18) would hamper the recruitment of additional protein subunits at the 5
´
 
-side of the damaged base (Figure 6a). 
On the other hand, the MtOGT::E1X-dsDNA crystal structure itself does not 
provide any indication of the dynamics of the alkylated-DNA damage reversal 
performed by MtOGT. Therefore, we can also assume that the binding of co-
oriented MtOGT monomers on to the modified strand could be favoured on 
assembly of protein clusters with components that display unbiased binding to both 
strands. To visualize the former situation, we reiterate the superimposition 
procedure mentioned above, by omitting the chain B symmetry mate. We obtained 
a model of MtOGT protein clusters (Figure 6b) that proves to be more compact 
compared with the one proposed for hAGT [46,47], possibly due to the structural 
plasticity of MtOGT, which could allow more crowded protein assembling on to 
DNA. It is interesting that the DNA binding-associated repositioning of the flap 
(see Figure 3) enables additional contacts between adjacent subunits. In particular, 
residues 32–34 of chain 2 are clamped between the active site entrance of the same 
chain, and the turn element of the HTH motif of adjacent chain 3 (residues 100–
105) (Figure 6b, inset on the left), thus strengthening our hypothesis of a possible 
direct contribution of the flap to cooperative DNA binding. Moreover, by 
considering chains 1 and 5 in our model (Figure 6b, inset on the right) we noticed 
that the N-terminal domain, random-coiled region of chain 1 collides with the tail  





Figure 6: Structure-based model of MtOGT clustering on to a DNA duplex 
(a) The possible negative effect of the presence of a MtOGT monomer (‘B sym. mate’), which is 
bound to the complementary strand opposing the lesion, on the growth of the protein cluster towards 
the 5_-end of the damaged strand. (b) Structure-based model of five co-oriented MtOGT monomers 
assembled on to the same dsDNA molecule; the zoomed images show the interchain contacts 
observed at the chain 2/chain 3 (left) and chain 1/chain 5 (right) interfaces; the colour codes for 
protein domain and DNA strand identification appear at the top of the panel. In (a) and (b), the 
protein chains are rendered as on the surface and the DNA appears as a cartoon. (c) Schematic 
representations of the protein–DNA assemblies depicted in (a) and (b), viewed perpendicular to the 
dsDNA axis; the MtOGT monomers that bind bases of the damaged or intact strand are depicted as 
red or green ovals, respectively; the dashed ovals represent the MtOGT subunit that would come 
into collision with preassembled monomers. 
of chain 5. This analysis suggests that both short- and long-range steric hindrance 
phenomena could play a role in regulating MtOGT–DNA association and 
dissociation, resulting in protein clusters that are capable of self-limiting their own 
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size, similar to what has been experimentally determined by direct atomic force 
microscopy studies of hAGT [48]. 
DISCUSSION 
The architecture of the protein–DNA complexes revealed by the MtOGT::E1X-
dsDNA crystal structure could provide a potential solution to an inconsistency 




Indeed, in spite of the fact that previous X-ray crystallography-based studies 
revealed a 1:1 protein:modified DNA stoichiometry [24,25,35]: (i) the cooperative 
binding of DNA has been demonstrated as a bona fide activity of hAGT [42-47], 
(ii) structure-based models of hAGT/dsDNA supramolecular complexes have been 
built and experimentally tested in solution [46] and, more importantly, (iii) the 
protein assembling into discrete clusters on physiological DNA substrates was 
directly observed by AFM-based experiments [48]. 
Several authors have analysed the possible functional benefits of performing 
alkylated-DNA direct repair in a cooperative manner. It has been pointed out that 
cooperative assembly of protein–DNA complexes might contribute to the 
efficiency of lesion search and removal, by concentrating the repair activity on the 
DNA substrate at a higher density than that expected in a non-cooperative DNA-
binding model [45]. Furthermore, a small protein cluster size could allow tracking 
of a lesion wherever short regions of free DNA were made available, i.e. during 
DNA replication and transcription, on chromatin remodelling [49]. Moreover, an 
inherent capability of the protein of limiting its own distribution on DNA could 
influence the rates of binding to and dissociation from the target, and hence the 
kinetics of the lesion search; in fact, the repositioning of a subunit placed in the 
middle of a single long protein cluster should probably be slower than the 
repositioning of subunits mapping at the ends of many short clusters [45,48]. 




Figure 7: Preliminary model of MtOGT-mediated direct alkylated DNA repair 
Schematics of possible modes of DNA binding, protein cluster assembly and protein–DNA complex 
dismantling in M. tuberculosis emerging from crystallographic studies. The single steps are 
described under ‘Discussion’. 
These arguments could work well with our results to outline a preliminary model 
of alkylated-DNA recognition and repair performed by MtOGT (Figure 7). In 
principle, to guarantee efficient scouting of alkylated bases inside the genome, both 
intact and damaged DNA molecules should represent a ligand for MtOGT. 
However, the binding of the protein to an adduct-free DNA region could be less 
efficient compared with the binding to an alkylated substrate, or the protein could 
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form suboptimal protein clusters (Figure 7, step 1a), leading to a weaker assembly 
(or an easier dissociation) of the protein–DNA complex. Our structural studies 
show that the insertion of a modified base inside the MtOGT active site triggers 
conformational modifications of solvent-exposed regions of the protein which 
could act as a signal that a lesion has been encountered (Figure 7, step 1b). 
Additional protein subunits could now be tightly packed, also by virtue of their 
peculiar structural flexibility, at the 5
´
-side of the lesion, where they undergo the 
same structural rearrangements to host extrahelical nucleobases in their active site. 
In this way, the GC-rich mycobacterial DNA could be scanned, at a fixed space 
interval, for the presence of other alkylated sites (Figure 7, step 2). 
Our present results suggest that, although an O-alkylated guanine is a potential 
substrate for the catalysis (leading to permanent protein inactivation), both purine 
bases could behave as reversible protein ligands; as a consequence, an unmodified 
guanine temporarily occupying the MtOGT active site could be safely checked for 
chemical modifications. This corroborates the concept that identifies, in the 
alkylated-DNA, direct damage reversal performed by OGTs, a smart system to 
oversee genome quality [49]. Finally, the conformational changes induced in 
MtOGT by its association with DNA appear to directionally bias protein–protein 
interaction towards the 5´-end of the modified strand; however, the harmful 
sequestration of MtOGT in the form of a continuous coat on the DNA substrate 
could be limited either by steric hindrance phenomena involving co-oriented 
monomers (Figure 7, step 3a) or by the association of an MtOGT subunit with the 
intact strand region opposing the alkylated base (Figure 7, step 3b), leading to the 
release of the unreacted monomers into the free protein pool (Figure 7, step 4), 
ready to initiate a new cycle. 
Further experiments, using different DNA substrates and crystallization-
independent techniques, have been undertaken to verify this model. 
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Synthesis of eX and of the oligonucleotide d(GCC ATG eX CTA GTA) 
(ON473) 
Unless otherwise stated, all solvents used were anhydrous. TLC was performed on 
TLC plates precoated with silica gel (silica gel/TLC-cards, UV 254, Merck). 
Compounds were detected using UV light (254 nm), heating (for the detection of 
dimethoxytrityl group; orange colour). The purity of the prepared compounds was 
determined by LC-MS using a Waters AutoPurification System with 2545 
Quarternary Gradient Module and 3100 Single Quadrupole Mass Detector using 
Luna C18 column (100 x 4.6 mm, 3 μm, Phenomenex) at a flow rate of 1 ml/min. 
Mass spectra were collected on an LTQ Orbitrap XL (Thermo Fisher Scientific) 
using ESI ionisation. NMR spectra were collected in DMSO-d6 or CDCl3 on a 
Bruker AVANCE 400 (1H at400.0 MHz, 13C at 100.6 MHz, and 31P at 162.0 
MHz) and/or Bruker AVANCE 500 (1H at 500.0 MHz, 13C at125.7 MHz, and 31P 
at 202.3 MHz) NMR spectrometers. Chemical shifts (in ppm, δ scale) were 
referenced to the residual DMSO-d6 signal (2.5 ppm for 1H and 39.7 ppm for 
13C). 31P NMR spectra were referenced to H3PO4 (0 ppm) as an external 
standard. Coupling constants (J) are given in Hz. 
3’,5’-Bis-O-(tert-butyldimethylsilyl)-O6-[(2,4,6-trimethylphenyl)sulfonyl]-2‘-
deoxyguanosine 2 
The title compound was synthesized according to published procedure [Hayakawa 
Y, Hirose M, & Noyori R(1993) O-Allyl protection of guanine and thymine 
residues in oligodeoxyribonucleotides. J Org Chem, 58(20):5551-5555] in 82% 
yield. 
3’,5’-Bis-O-(tert-butyldimethylsilyl)-6-O-hydroxyethyl-2’-deoxyguanosine 3 
DABCO (9.5 g, 84.7 mmol) was added to the stirred solution of 2 (14.36 g, 21.18 
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mmol) in THF (200 ml). The reaction mixture was stirred at rt for 3 h. 
Ethylenglycol (12 ml, 215.17 mmol) and DBU (9.5 ml, 63.59 mmol) were added. 
The mixture was stirred at rt 1 h and evaporated. The final product was obtained by 
chromatography on silica gel (elution with a gradient of ethyl acetate in toluene) in 
50% yield (5.77 g, 10.69 mmol) in the form of yellowish oil. 
1H NMR (499.8 MHz, DMSO-d6): 0.03, 0.04, 0.105, 0.107 (4 × s, 4 × 3H, 
CH3Si); 0.86, 0.89 (2 × s, 2 ×9H, (CH3)3CSi); 2.55 (ddd, 1H, Jgem = 13.2, J2'b,1' 
= 6.0, J2'b,3' = 3.3, H-2'b); 2.73 (ddd, 1H, Jgem = 13.2, J2'a,1' =7.6, J2'a,3' = 5.7, 
H-2'a); 3.64 (dd, 1H, Jgem = 11.0, J5'b,4' = 4.4, H-5'b); 3.72 (dd, 1H, Jgem = 11.0, 
J5'a,4' = 6.0, H-5'a); 3.75 (bq, 2H, J = 5.2, OCH2CH2OH); 3.82 (ddd, 1H, J4',5' = 
6.0, 4.4, J4',3' = 2.7, H-4'); 4.41 (m, 2H, OCH2CH2OH); 4.51 (ddd, 1H, J3',2' = 
5.7, 3.3, J3',4' = 2.7, H-3'); 4.89 (bt, 1H, J = 5.2, OH); 6.20 (dd, 1H, J1',2'= 7.6, 6.0, 
H-1'); 6.42 (bs, 2H, NH2); 8.05 (s, 1H, H-8). 
13
C NMR (125.7 MHz, DMSO-d6): -5.33, -5.29, -4.77, -4.59 (CH3Si); 17.90, 
18.15 (C(CH3)3); 25.87, 25.96 ((CH3)3C); 38.88 (CH2-2'); 59.44 (OCH2CH2OH); 
62.92 (CH2-5'); 67.64 (OCH2CH2OH); 72.34 (CH-3'); 82.49 (CH-1'); 87.14 (CH-
4'); 114.06 (C-5); 137.54 (CH-8); 154.15 (C-4); 159.92 (C-2); 160.64 (C-6).  
HR-ESI C24H46O5N5Si2 [M+H]
+
 calcd 540.30320, found 540.30323 
1-N-6-O-Ethano-2’-deoxyxanthosine 6 
1M TBAF in THF (3 ml) was added to the solution of 5 (1.12 g, 2.14 mmol) in 
THF (8 ml). The reactionmixture was stirred at rt for 45 min. The reaction mixture 
was diluted with ethanol (20 ml) and Dowex 50 in TEA form (5 g) was added. The 
suspension was stirred 5 min and filtrated. The filtrate was evaporated and the final 
product was obtained by chromatography on silica gel (elution with a gradient of 
0–100% ethanol/acetone/water/ethyl acetate 1:1:1:4 in ethyl acetate) in 87% yield 
(0.55 g, 1.87 mmol) in the form of white amorfous solid. 
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1H NMR (600.1 MHz, DMSO-d6): 2.24 (ddd, 1H, Jgem = 13.2, J2'b,1' = 6.2, 
J2'b,3' = 3.2, H-2'b); 2.55 (ddd, 1H, Jgem = 13.2, J2'a,1' = 7.6, J2'a,3' = 5.9, H-2'a); 
3.50 (ddd, 1H, Jgem = 11.8, J5'b,OH = 5.5, J5'b,4' = 4.9, H-5'b); 3.57(dt, 1H, Jgem 
= 11.8, J5'a,4' = J5'a,OH = 4.9, H-5'a); 3.97 (td, 1H, J4',5' = 4.9, J4',3' = 2.9, H-4'); 
4.21 (m, 2H, NCH2CH2O); 4.35 (m, 1H, J3',2' = 5.9, 3.2, J3',OH = 4.1, J3',4' = 
2.9, H-3'); 4.77 (m, 2H, OCH2CH2N); 4.94(bdd, 1H, JOH,5' = 5.5, 4.9, OH-5'); 
5.30 (d, 1H, JOH,3' = 4.1, OH-3'); 6.16 (dd, 1H, J1',2' = 7.6, 6.2, H-1'); 8.12(s, 1H, 
H-8). 
13C NMR (150.9 MHz, DMSO-d6): 39.42 (CH2-2'); 42.64 (NCH2CH2O); 61.81 
(CH2-5'); 68.06(OCH2CH2N); 70.86 (CH-3'); 83.55 (CH-1'); 88.03 (CH-4'); 
119.45 (C-5); 137.56 (CH-8); 148.95 (C-4); 154.82 (C-2); 157.92 (C-6).  
HR-ESI C12H14O5N4Na [M+Na]+ calcd 317.08564, found 317.08561 
5’-O-Dimethoxytrityl-1-N-6-O-ethano-2’-deoxyxanthosine 7 
DMTrCl (0.76 g, 2.24 mmol) was added in two portions to the solution of 6 (0.55 
g,1.87 mmol) in pyridine(40 ml). The reaction mixture was stirred at rt overnight. 
The solvent was removed in vacuo and the product was obtained by purification by 
chromatography on silica gel (elution with a gradient of 0–10% ethanol in 
chloroform) in 45% yield (0.5 g, 0.84 mmol) in the form of white foam. 
1H NMR (499.8 MHz, DMSO-d6): 2.57 (ddd, 1H, Jgem = 13.5, J2'b,1' = 6.8, 
J2'b,3' = 4.4, H-2'b); 2.65 (dt, 1H, Jgem = 13.5, J2'a,1' = J2'a,3' = 6.4, H-2'a); 3.09 
(dd, 1H, Jgem = 10.2, J5'b,4' = 3.5, H-5'b); 3.26 (dd, 1H, Jgem = 10.2, J5'a,4' = 
6.7, H-5'a); 3.719, 3.725 (2 × s, 2 × 3H, CH3O-DMTr); 3.97 (dt, 1H, J4',5' = 6.7, 
3.5, J4',3' = 3.5, H-4'); 4.19 (m, 2H, NCH2CH2O); 4.33 (m, 1H, J3',2' = 6.4, 4.4, 
J3',OH = 4.5, J3',4' = 3.5, H-3'); 4.74 (m, 2H, OCH2CH2N); 5.35 (d, 1H, JOH,3' = 
4.5, OH-3'); 6.21 (dd, 1H, J1',2' = 6.8, 6.4, H-1'); 6.80, 6.83 (2 × m, 2 × 2H, H-m-
C6H4-DMTr); 7.17-7.26 (m, 7H, H-o-C6H4-DMTr, H-m,p-C6H5-DMTr); 7.34 
(m, 2H, H-o-C6H5- DMTr); 8.00 (s, 1H, H-8). 
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13C NMR (125.7 MHz, DMSO-d6): 38.91 (CH2-2'); 42.58 (NCH2CH2O); 55.16, 
55.18 (CH3O-DMTr); 64.47 (CH2-5'); 68.00 (OCH2CH2N); 70.88 (CH-3'); 83.53 
(CH-1'); 85.59 (C-DMTr); 86.23(CH-4'); 113.20, 113.24 (CH-m-C6H4-DMTr); 
119.72 (C-5); 126.75 (CH-p-C6H5-DMTr); 127.86, 127.87 (CH-o,m-C6H5- 
DMTr); 129.86, 129.90 (CH-o-C6H4-DMTr); 135.71, 135.78 (C-i-C6H4-DMTr); 
137.77 (CH-8); 145.10 (C-i- C6H5-DMTr); 148.98 (C-4); 154.81 (C-2); 157.70 (C-
6); 158.16, 158.20 (C-p-C6H4-DMTr). C33H33O7N4 [M+H]+ calcd 597.2349, 
found 597.2353 
3’-O-(2-Cyanoethyl-N,N-diisopropyl)phosphoramidite-5’-O-dimethoxytrityl-1-
N-6-O-ethano-2’- deoxyxanthosine 8 
2-Cyanoethyl N,N-diisopropylchlorophosphoramidite (0.33 ml; 1.5 mmol) was 
added to a solution of 7 (0.3 g; 0.5 mmol mmol) and DIPEA (0.52 ml; 3.0 mmol) in 
DCM (5 mL). The reaction mixture was stirred 2 h at rt After that, the solution was 
diluted with ethyl acetate (50 ml) and extracted with saturated solution of sodium 
hydrogencarbonate (3 x 20 ml). The organic layer was dried over anhydrous 
sodium sulfate and evaporated. The product was purified by chromatography on 
silica gel (elution with a gradient of 0–50% acetone in toluene; silica gel was 
buffered with TEA). Lastly, phosphoramidite was freeze-dried from benzene. 
Yield 0.25 g (62%). 
31P (162 MHz; d6-benzene) 148.92; 148.90. 
Synthesis and purification of the ON473 oligonucleotide 
Oligonucleotide ON473 (Supplementary Table 1 and Supplementary Figure 2) was 
synthesized as DMT OFF using monomers with base-labile nucleobase protecting 
groups (PAC) and standard phosphoramidite condensation protocol. Synthesis was 
performed on a 0.5 μmol scale on 5'-dimethoxytrityl-N-benzoyl-2'- 
deoxyadenosine-3'-succinoyl-LCAA CPG using GenSyn V02 DNA/RNA 
synthesizer. Modified units eX were also incorporated using standard 
  Chapter 3 
80 
 
phosphoramidite condensation protocol. After the solid-phase synthesis, 
oligonucleotide ON473 was deprotected using gaseous ammonia. The column was 
inserted into the pressure vessel and treated with gaseous ammonia (0.7 MPa) for 
1.5 h to remove acyl protecting groups and to release the final product from the 
solid support. After that, the deprotected DNA was washed off of the column by a 
0.1 M TEAA buffer and purified using ion exchange chromatography. Isolated 
yield 65 %. 
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 (a) The modified base appears in bold; E1X-dsDNA used in co-crystallization was 
obtained by annealing the ON473 and anti-ON473 oligonucleotides. (b) Triplets 
encoding the substituting aminoacid in the “sense” oligonucleotide appears in bold. 
(c) The ds-DNA
met
 substrate used in VG-based assays was obtained by annealing 
the UP
met
 (the methylguanine is labeled by an asterisk) and DOWN 
oligonucleotides. (d) The unmodified dsDNA probe used in EMSA analyses was 
obtained by annealing the A
+
 (“TMR” indicates the TAMRA
TM





  Chapter 3 
82 
 
Supplementary Table 2 
 
Kinetic constants of the reaction catalysed by the indicated MtOGT variants - 
The concentration value of dsDNA
met
 refers to the amount of mono-methylated 
double stranded DNA used in the SNAP Vista-green
TM
 reagent (VG)-based 
competitive assays. k and KVG correspond to the rate of covalent linkage and the 
dissociation constant for the free enzyme and free VG reagent, respectively. 
KDNA
met
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Supplementary Figure 1 
 








6-O-Mesitylenesulfonyl derivative 2 was prepared according to published 
procedure [Hayakawa, Y., Hirose, M., and Noyori, R. (1993) O-Allyl protection of 
guanine and thymine residues in oligodeoxyribonucleotides. J Org Chem 58, 5551-
5555] in 82% yield. 6-O-Ethyleneglycol derivative 3 was prepared via DABCO 
quarternary intermediate in 50% yield. 6-O-hydroxyethylxanthosine derivative 4 
was obtained by NaNO2 mediated deamination in 53% yield. Subsequent five-
membered ring closure was accomplished by treatment with tosylchloride in 
pyridine affording derivative 5 in 30% yield. Desilylation (87%) followed by 
dimethoxytritylation (45%) afforded protected 
e
X nucleoside 7. Finally, nucleoside 
7 was converted to 
e
X phosphoramidite monomer employing standard procedure 
with 62% yield. 
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Supplementary Figure 2 
Analyses of the d(GCC ATG eX CTA GTA) oligonucleotide (ON473) 
 
Chromatogram of ON473 after purification using ion exchange chromatography. Gradient 0-
30%B30min 55 oC [A = 20mM AcONa, 20mM NaCl, 10% ACN; B = 20mM AcONa, 1.5M 
NaCl, 10% ACN] 
 
MALDI MS of ON473 
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Supplementary Figure 3 
 
 
MtOGT is able to host unmodified extra-helical DNA bases in its active site - a. Close-up of the 
active site of superposed chains B and C of the MtOGT::E1X-dsDNA structure; the adenine bases 
are colored applying the same color code used for the corresponding protein chain. b. Surface 
representation of the active site of optimally superimposed MtOGT::E1X-dsDNA (monomer B) and 
hAGT::C
#
-dsDNA (monomer B), which are observed to bind an unmodified nitrogenous base in the 
corresponding crystal structure; as a matter of clarity, images are represented side by side. 
 










Analyses of macromolecular interactions sustaining 
















In order to combat the potential genotoxic and mutagenic effects of DNA-
alkylation by endogenous and exogenous compounds, all living species, including 
Mycobacterium tuberculosis (MTB) 1 deploy different strategies, depending upon 
the entity and the nature of the damage, and the physiologic state of the cell. These 
repairing mechanisms include i) the removal of a short, lesion-containing 
oligonucleotide followed by DNA new synthesis, through the action of the 
Nucleotide Excision Repair (NER) system [2]; and ii) the conversion of alkylated-
nucleobases back to their unmodified original state, through a single step reaction 
catalyzed by an alkylated-DNA protein alkyltransferase protein (referred to as 
AGT, MGMT or OGT) [3,4].  
Bacterial NER is capable to recognize and repair a broad range of damaged-DNA 
substrates by utilizing three core proteins (UvrA, UvrB and UvrC), which act co-
operatively to form the damage detection/verification, pre-incision and incision 
complexes that are involved in first events of the multi-step repairing cascade [2]. 
UvrA, the first enzyme acting in bacterial NER, is an ABC ATPase responsible for 
the lesion sensing activity (which is triggered by DNA substrates characterized by a 
certain degree of geometry distortion), and the recruitment of UvrB at the damaged 




DNA site. Moreover, UvrA is also a key player in the Transcription Coupled NER 
pathway, by virtue of its association to the Mfd protein, the bacterial functional 
equivalent of the Transcription Coupled Repair Factor (TCRF) [5]. 
Recent investigations carried out in our laboratory led to the biochemical 
characterization of MTB UvrA (MtUvrA) and the X-ray crystallography-based 
structural description of the protein in its ligand-free state [6]. As observed in other 
structures of UvrAs reported so far (e.g. the ADP-bound UvrA [7] and the 
UvrA/UvrB complex [8] from Bacillus stearothermophilus, as well as the 
Thermotoga maritima ortholog in complex with a modified double-stranded DNA 
[9]), the protein architecture is organized around a globular catalytic core, hosting 
two nucleotide binding sites, and exposing the DNA-contacting Zinc-finger on its 












FIGURE 1: (a) Cartoon representation of a MtUvrA subunit; the asterisks label the position of the 
nucleotide binding sites; a close-up view of the C-terminal Zn finger appears in the inset. The UvrB 
binding domain (UvrB-BD) and the insertion domain (ID) are colored blue and yellow, respectively 
and the two Zn modules are indicated [modified from 6]. 
 
 
In sharp contrast, the UvrB-binding domain (UvrB-BD) and the insertion domain 
(ID) (distinguishing UvrAs from the other ABC ATPases family members), are 
observed in a quite different conformation. In particular, both of the UvrB-BD of 




the functional MtUvrA dimer appear 90° rotated towards the ventral side of the 
protein compared to the position occupied by the equivalent region in B. 






















FIGURE 2: MtUvrA dimer organization. (a) Comparison between the functional dimeric 
assemblies of MtUvrA (upper side, left), BstUvrA (lower side, left) and TmUvrA (lower side, right) 
as viewed from their ventral surface, upon optimal superposition; the two catalytic cores in each 
dimer are coloured magenta and white in MtUvrA, orange and white in BstUvrA and cyan and white 
in TmUvrA; the UvrB-BD, the ID and the C-terminal Zn finger are invariably coloured blue, yellow 
and red, respectively; DNA appears in black. The inset depicts a close-up view of the peculiar 
interactions observed in the MtUvrA dimer on its ventral side; residues participating in main 
stabilizing contacts are shown as sticks [6]. 
 
In principle, the unprecedented conformation characterizing the MTB UvrA 
dimer could still allow the simultaneous binding of two UvrB monomers and DNA 
substrate, although we cannot exclude that these functional complexes could 
display a molecular architecture or a stoichiometry different from the one reported  













FIGURE 3: The AB damage sensor is shown as a cartoon in two different views. The view in a is 
related to that in b by a 90° rotation about the horizontal x axis. The two protomers of UvrA are 
shown in different shades of gray, with the signature domain II in cyan and blue. UvrB molecules 
are shown in different shades of orange. The positions of proximal and distal nucleotide binding 
sites are denoted by semi-transparent magenta and green spheres, respectively. In panel b, the 
boundaries of UvrA and UvrB are outlined modified from[8]. 
for the B. stearothermophilus UvrA2::UvrB2 assembly (figure 3) [8].  
Notably, studies in other bacterial and lower eukaryotic species revealed that 
alkyltransferase-like proteins (ATL) -which display structural similarity to genuine 
OGT, but lack the catalytic cysteine and the N-terminal domain-, strongly enhance 
the repair by NER of mutagenic adducts (including alkylated-guanine), which are 
otherwise poor substrates of this system [reviewed in 10,11], by directly interacting 
with UvrA (Figure 4). 
Overall these data highlight the importance of analyzing not only individual 
DNA-repair pathways in a given species, but also their reciprocal coordination 
when approaching the study of such a complex biochemical problem in a 
systematic way. These considerations represent the rationale that prompted us to 
undertake studies aimed at characterizing and/or disclosing macromolecular cross-
talks between the different machineries controlling DNA-repair in MTB. 
As part of the EU 7FP collaborative project “SysteMTb” the study of the 
“interaction network” of selected MTB proteins was performed, including crucial  

















FIGURE 4: OGTs directly repair alkylated bases through a suicidal reaction; ATLs (which are 
absent in higher eukaryotes) behave as molecular adaptors for UvrA, to allow the NER-dependent 
repair of non-helix distorting damaged bases. 
players in DNA-repair. Preliminary high throughput (HT) interaction analyses 
based on a liquid chromatography-based single-step affinity purification method 
followed by high-resolution mass spectrometry (LC-MS/MS), confirmed the 
capability of MtUvrA to directly associate with UvrB [12], while no interaction 
was detected between MtUvrA and ATL in the same experimental setting.  
Unexpectedly, these analyses disclosed an unprecedented interaction between 
MtOGT and UvrA (unpublished), signaling that, in MTB, a coordination between 
alkylated-nucleobase direct repair (by MtOGT) and NER could exist.  
Preliminary data obtained from Surface Plasmon Resonance (SPR)-based 
experiments, using the Biacore
TM
 platform, confirmed the direct association 
between pure preparations of recombinant MtUvrA -bearing a poly-His tag at its N-
terminus [6], and MtOGT (tag-free) [13]. The kinetic analysis of the 
MtUvrA::MtOGT complex formation allowed the determination of the dissociation 
constant (KD) of the complex that ranks in the low micromolar range (1.42*10
-6 




M), revealing the transient nature of this interaction. Notably, this value is 
comparable to that found for the well-described UvrA::UvrB complex from B. 
stearothermophilus. 
I describe hereafter the unpublished experiments we performed 1) to start to 
investigate the biochemical properties and the structural features of the 
MtUvrA::MtUvrB complex, and 2) to provide further independent confirmation to 
the direct assembling of the newly identified MtOGT::MtUvrA complex.  
MATERIALS AND METHODS 
Chemicals 
All reagents were obtained from Sigma-Aldrich unless otherwise specified. 
Construction of a plasmid driving the over-expression of MtUvrB in E. coli 
cells   
The complete open reading frame encoding UvrB of Mycobacterium tuberculosis 
H37Rv strain (Tuberculist entry: Rv1633) was amplified by PCR using 40 ng of 
MTCY06H11.01 bacmid DNA (Institut Pasteur, Paris, France), the Hotstar High 
fidelity polymerase (Qiagen) and the primers: UvrB_for (5'-
ATTAGCGATCGCCGTGCGCGCCGGCGGTCAC-3'-, Sgf I site is underlined) 
and UvrB_rev (5'- AATTGTTTAAACTCACTTCAGGCCGGCCGCG- 3', Pme I 
site is underlined). The Sgf I/Pme I-double digested PCR product was inserted into 
the pFN18A Halotag T7Flexi vector (Promega), linearized by the same restriction 
enzymes, adopting standard procedures [14], resulting in the pMtHaloUvrB 
expression plasmid, whose MtUvrB-encoding region was verified by sequencing 
(Eurofins MWG Operon). 
 
 




Expression and purification of MtUvrB  
Escherichia coli strain BL21(DE3) competent bacteria were transformed with 
pMtHaloUvrB expression construct and spread onto 2XTY-agar medium added 
by ampicillin (50µg/L). Freshly transformed colonies were dispersed in 1 L of 
2XTY-ampicillin medium in a 5 L flask, to reach a starting optical density at 600 
nm (O.D.600) of 0.1, and grown under vigorous shaking till an O.D.600 of 0.8 at 37 
°C. Upon a cold shock on an ice-water bath for 15 minutes, the bacterial culture 
was added of 0.1 mM Isopropyl β-D-1-thiogalactopyranoside, brought at 17 °C, 
and further grown overnight under vigorous shaking. The bacterial pellet obtained 
(8 g) was resuspended in 60 mL of lysis buffer (50 mM Hepes pH 7.5, 150 mM 
NaCl, 1 mM DTT) and the cells were disrupted using Ultrasonic processor 
(Vibra-Cell). The clear supernatant was obtained after a 30 min. centrifugation at 
16,000 g. 20 mL of a 25% HaloLink
TM
 resin slurry (Promega) (Scheme 1) 
(corresponding to 5 ml of settled resin) were equilibrated with the same lysis 
buffer and then incubated with the clear supernatant, under slight rotation for 2 
hours. Upon binding, the protein-laden resin was extensively washed in same 
lysis buffer, and incubated in the presence of the Tev protease (330 unit/mL resin 
bed volume) to trim the Halo-tag from the recombinant protein, under gentle 
rotation for 2 hours. Following this step, the resin was packed in a column and 
fractions containing tag-free MtUvrB were recovered, pooled and incubated with 
HisLink
 TM
 resin (Promega) (Scheme 1) to remove the Tev protease, following 
manufacturer’s instructions. MtUvrB fractions from this last step were pooled and 
concentrated up to 12 mg/mL and stored in aliquots at -80 °C, if not immediately 
used. The expression/purification procedure yields 6 mg of pure tag-free MtUvrB 
per liter of induced bacterial culture. 
Optimization of MtUvrA Expression and purification   
The procedure to express and purify MtUvrA was slightly modified from [6]. E. 
coli BL21(DE3) colonies harboring the plasmid pMtHisUvrA were dispersed in 4 L  










SCHEME 1: Procedure to obtain tag-free MtUvrB from a clarified lysate of E. coli cells 
transformed with pMtHaloUvrB 
of 2XTY-ampicillin medium to obtain a starting O.D.600 of 0.15. This culture was 
further grown at 37 °C under vigorous shaking until an O.D.600 of 1.0 was reached. 
Upon a 15 minutes cold shock and the addition of 0.15 mM IPTG, the bacterial 
culture was cultivated at 17 °C overnight for the expression of the His-tagged 
MtUvrA. Upon an immobilized metal affinity chromatography (IMAC) purification 
step using the Ni-NTA resin (Qiagen) -as described in [6]-, the pure protein sample 
was loaded onto a column pre-packed with heparin-functionalized resin (HiTrap 
Heparin HP, GE healthcare) and pre-equilibrated with buffer A (20 mM Tris-HCl 
pH 8.0). The bound protein was then eluted using linear 0-2 M NaCl gradient. The 
fractions corresponding to the eluted DNA-free protein, were pooled and 
concentrated by ultrafiltration (membrane NMWCO=100 kDa, Vivascience) up to 
1 mg/mL. Preparative SEC was performed using a Sephacryl S-200 High 
Resolution 16/60 (GE healthcare), by fluxing buffer B (20 mM Tris-HCl, pH 8.0, 
500 mM NaCl) as the mobile phase. The MtUvrA containing fractions were 
pooled, concentrated up to 5 mg/mL and stored in small aliquots at -80 °C, if not 
immediately used.  The optimized expression/purification procedure yields 0.6 mg 








Protein co-fractionation experiments using SEC  
SEC-based protein co-fractionation experiments were performed using an Akta 
FPLC instrumentation and the Superdex 200 5/150 GL or Sephacryl S-200 High 
Resolution 16/60 columns (GE healthcare) -as specified in the figures-, pre-
calibrated with standard proteins following manufacturer’s instructions, and using 
the buffer B (see above) as the mobile phase.  Co-elution experiments of MtUvrA 
and MtOGT in the presence of single stranded DNA (ssDNA) were conducted 
using the oligonucleotide (5'-TTAAGTTTAAACGAACCCGACCTGCCGC 
ATCA-3'). 
 
RESULTS AND DISCUSSION 
High yield expression and purification of a recombinant, tag-free version of 
MtUvrB 
The expression vector pMtHaloUvrB was designed to drive in E. coli the over-
expression of a full-length MtUvrB recombinant protein, which bears, at its N-
terminus, a Halo-tag moiety that could be removed by Tev-mediated proteolysis 
(Scheme 1).  
Several trials, systematically exploring the temperature and time of bacterial 
growth and induction of the pMtHaloUvrB-transformed E. coli BL21(DE3) strain, 
as well as the concentration of IPTG, were carried out in order to obtain the protein 
at high yields in the soluble fraction of the bacterial lysate. The best expression 
conditions in terms of protein yield and solubility correspond to an overnight 
induction of the protein at 17 °C by adding 0.1 mM IPTG (Figure 5). The purified 
MtUvrB protein is highly homogeneous, and behaves as a probable dimer in 






















FIGURE 5: SDS-PAGE analysis, using a 7.5 % acrylamide/bis-acrylamide gel, of the T: total 
lysate of the induced pMtHaloUvrB-transformed bacteria, P: insoluble fraction of the lysate upon 
centrifugation, S: soluble fraction of the lysate upon centrifugation. FT (flow-through) and W 
(wash) refer to proteins in the S fraction that do not bind or do not specifically associate to the 
HaloLink resin, respectively. MWM: molecular weight standards. The gel was stained in 

















FIGURE 6: SEC analysis of MtUvrB at the end of the purification procedure, using a pre-calibrated 
Superdex 200 5/150 GL column.  
 
Modified procedure for expression and purification of MtUvrA 
The expression conditions to obtain the His-tagged recombinant variant of MtUvrA 
were modified with respect to the published procedure [6] in order to increase the 
percentage of the recombinant protein in the soluble fraction of the bacterial lysate 
after cell disruption.  














FIGURE 7: SDS-PAGE analysis (7.5 % acrylamide/bis-acrylamide gel, CBB staining), of the T: 
total lysate, P: insoluble fraction of the lysate upon centrifugation, and S: soluble fraction of the 
lysate upon centrifugation, of pMtUvrA-transformed bacteria induced (by the addition of 0.15 mM 













FIGURE 8: SDS-PAGE analysis (7.5 % acrylamide/bis-acrylamide gel, CBB staining), of the T: 
total lysate of the pMtUvrA-transformed bacteria induced to express the MtUvrA protein by 
following the modified procedure, P: insoluble fraction of the lysate upon centrifugation, S: soluble 
fraction of the lysate upon centrifugation. FT (flow-through) and W (wash) refer to proteins in the 
loaded sample that do not bind or do not specifically associate to the Ni-NTA resin, respectively. 
MWM: molecular weight standards.  
 
 




Indeed, at each step of the purification protocol a large proportion of the protein is 
lost; therefore, by augmenting the amount of the starting soluble protein we were 
able to add two further FPLC-based purification steps, namely a pseudo-affinity 
chromatography using a heparin-functionalized resin, followed by SEC. According 
to the new protocol, E. coli BL21(DE3) cells harboring the plasmid pMtHisUvrA 
were grown overnight at 17 °C after protein induction instead of 4 hours at 30 °C 
as previously described [6]. As shown in Figure 7, the percentage of the protein in 
the soluble fraction upon centrifugation of the disrupted bacteria is increased, 
without affecting the behavior of the protein during Ni-NTA affinity purification 

















FIGURE 9: A. chromatogram showing the MtUvrA elution in a sharp peak from the HiTrap 
Heparin HP column, at 2/3 of the linear salt gradient, corresponding to a 1.5 M NaCl molar 
concentration. The blue trace corresponds to the reading of the absorbance at 280 nm; the green 
graph follow the NaCl gradient. 
 
 
We previously observed that MtUvrA tends to be contaminated by small traces of 
damaged/fragmented genomic DNA produced during cell disruption; this 
phenomenon, while not affecting the “crystallizability” of the protein [6], could 
interfere with protein-protein and protein-DNA studies. The pure MtUvrA protein 
obtained from the IMAC step (Figure 8), was therefore subjected to a further 




chromatographic purification using a heparin-functionalized resin. In this case the 
MtUvrA protein elutes in a DNA-free form at a high salt concentration (1.5 M 
NaCl), where the high ionic strength of the elution buffer could exert a stabilizing 
effect upon the the ligand-free protein (Figure 9).  
In order to reach a salt concentration in solution compatible with protein-protein 
interaction studies, MtUvrA was subjected to SEC in the presence of fixed 
decreasing concentrations of NaCl, in order to reveal the minimum salt 
concentration required to maintain the solubility of the protein. These analyses 
revealed that below a 500 mM NaCl concentration in the SEC mobile phase 
MtUvrA tends to aggregate and precipitate either during the injection or into the 
column (not shown). Therefore, a buffer composed of 20 mM Tris-HCl pH 8.0 and 
500 mM NaCl was selected as the mobile phase during SEC-based interaction 
studies. The prevailing oligomeric state of the MtUvrA protein, purified following 






















FIGURE 10: SEC analysis of MtUvrA at the end of the optimized purification procedure, using a 
pre-calibrated Superdex 200 5/150 GL column. 




MtUvrA2::MtUvrB2 complexes formation in solution in the absence of DNA 
substrate 
A huge number of most recent studies in other bacterial species, using a wide array 
of technologies ranging from X-ray crystallography to cutting-edge single molecule 
imaging techniques 16, shed light on the structural details and the dynamics of 
macromolecular interactions supporting the first UvrABC endonuclease-mediated 
events of the NER cascade.  
In particular, the stoichiometry of the damage tracking assembly has recently 
been confirmed through the analysis of the crystal structure of the B. 
stearothermophilus UvrA2::UvrB2 complex [8]. 
In order to disclose the capability of MtUvrA to MtUvrB to associate in solution 
in the absence of any DNA substrate (as suggested by the the LC-MS/MS-based 
HT screening [12]) we used the homogenous preparations of the two proteins in 
SEC-based co-fractionation experiments on small-scale (Figure 11A).   
The recombinant versions of MtUvrA and MtUvrB co-elute from the column in a 
single peak, showing a Ve = 1.53 mL. This value corresponds to a 527 kDa 
molecular mass of the eluted material, which could in principle be contributed by 
more than one dimer of each protein. We subsequently performed a SEC 
experiment exploiting a Sephacryl S-200 High Resolution 16/60 column (Figure 
11B) In this case the calculated molecular mass of the eluted material suggests the 
formation of a MtUvrA2::MtUvrB2 complex in solution. 
 
SEC-based analyses of MtOGT/MtUvrA association 
To confirm the direct interaction between MtOGT and MtUvrA, which was 
disclosed by the HT LC-MS/MS experiments and confirmed by SPR-based assays 
(not shown), we performed the same set of SEC-based analyses, using a mixture of 
the two pure proteins at a 2:1 molar ratio. The resulting data (Figure 12A) cannot 
be unambiguously interpreted; in facts, although the chromatogram show two 




partially overlapping absorption peaks (peaks 1 and 2 in Figure 12A), the SDS-
PAGE analysis of the eluted fractions revealed the presence of a significant amount 
of MtUvrA in the second peak that corresponds to a Ve=2.47 mL, and to a 
calculated molecular mass of less than 10 kDa, even lower than the one expected 




















FIGURE 11: SEC analysis of the MtUvrA/MtUvrB direct association in solution, using a pre-
calibrated A. Superdex 200 5/150 GL column, and B. Sephacryl S-200 High Resolution 16/60 
column. In both panels the inset shows the SDS-PAGE analysis of the main peak-corresponding 
eluted fractions (fx #) using 7.5% acrylamide/bisacrylamide gel stained by coomassie brilliant blue 








































FIGURE 12: SEC analysis of A. a 2:1 MtOGT:MtUvrA mixture; B. a 1:1.4:2 MtUvrA:ssDNA: 
MtOGT mixture, using a using a pre-calibrated Superdex 200 5/150 GL column. In both panels the 
inset shows the SDS-PAGE analysis (15% acrylamide/bis-acrylamide gel, CBB staining) of the 
eluted fractions (fx #); MWM: molecular weight standards. In B. aliquots of the individual proteins 
(MtUvrA, MtOGT) are also shown; load: MtUvrA+MtOGT+ssDNA sample before SEC-
fractionation.    
 
 
We also preincubate MtUvrA in the presence of a potential ssDNA substrate, 
followed by the addition of MtOGT, prior to performing the SEC analysis 
described above (Figure 12B). However, also in this case, the three components of 
the injected mixture (namely MtUvrA, ssDNA and MtOGT) co-elute in a broad 
peak, of very poor quality, and  the analysis of the corresponding chromatogram 




did not allow us to make speculations on the oligomerization state of the complex. 
Similar contradictory data were obtained using the Sephacryl S-200 High 



















FIGURE 13: SEC analysis of a 1:1.4:2 MtUvrA:ssDNA: MtOGT mixture, using a using a pre-
calibrated Sephacryl S-200 High Resolution 16/60 column. The inset shows the SDS-PAGE 
analysis (15% acrylamide/bis-acrylamide gel, CBB staining) of the eluted fractions corresponding 
to the main peak (fx #); MWM: molecular weight standards.  
 
 
Further analyses, exploiting different techniques characterized by a higher 
resolution potential (e.g. analytical ultracentrifugation), will be performed to 
confirm the subunit composition of the MtUvrA/MtUvrB-containing assemblies 
(also in the presence of known ligands of both proteins, such as ATP/ADP or short 
DNA molecules), as well as to obtain additional information about the 
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MTB lives and survives inside the human macrophages, conserving an overall high 
level of genetic stability despite the continuous exposure to host-generated DNA 
damaging assaults. This observation indirectly signals that efficient DNA-repairing 
functions are present in MTB. Most of these mechanisms require a direct and 
dynamic association between multiple proteins; therefore, studies aimed at 
characterizing these intra- and inter-pathway macromolecular interactions could 
represent the basis to the description of mycobacterial DNA repair as a whole, and 
in the broader context of MTB biology, also including potential cross-talks with the 
host cell in the course of TB pathogenesis. 
The research presented in this Thesis already allowed us to gain new insights into 
biochemical and structural aspects of single proteins involved in MTB alkylated-
DNA repair (the suicidal MtOGT protein and the NER components MtUvrA and 
MtUvrB) and of their reciprocal association. In order to obtain a detailed 
description of the association dynamics and the oligomerization state of the 
macromolecular complexes revealed by these studies, also in the presence of 
different DNA substrates and/or specific small-molecule effectors, we planned to 
include in our future analyses experiments based on alternative bio-physical 
technique, such as bio-layer interferometry. Moreover, the design and/or the 
optimization of reproducible procedures to express in E. coli and purify to the 
homogeneity and at high yield key components of the MTB DNA-repair toolkit, as 
described in this Thesis, will speed up their further structural characterization. In 
this context, we are aware that obtaining crystals suitable for X-rays 
crystallography analysis of huge, multi-domain, flexible proteins and/or 
macromolecular complexes is challenging; however, different actions could be 
implemented to overcome this possible obstacle. First we could try crystallization 
of the proteins in the presence of different substrates and/or stabilizing chemical 




species, as they will be revealed by thermal shift analysis. Moreover, preliminary 
low resolution structural characterization of selected protein-protein and protein-
DNA complexes could be carried out in solution by Small-Angle X-ray Scattering 
(SAXS) experiments using synchrotron radiation. Finally, due to the large size of 
the expected macromolecular complexes, alternative molecular imaging techniques 
(such as Atomic Force Microscopy or Single Molecule Electron Microscopy) will 
be considered. 
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